# LLM Query Results

## ğŸ” Query
ë…ê¸°ì—´ê³¼ ë¹„ìŠ·í•œ ë§¤ê°œì²´ë¡œ ì¸í•œ ê°ì—¼ë³‘ì€?

### ğŸ“š Context

<details>
<summary>1. 2522_5676_Leptospira interrogans.html (2/4)</summary>

ì œëª©: Leptospira interrogans  2. ê°ì—¼   1) ê°ì—¼ëœ ë™ë¬¼, íŠ¹íˆ ë“¤ì¥ì˜ ì†Œë³€ì„ í†µí•´ ì£¼ë¡œ ì „ì—¼ëœë‹¤. í•´ë‹¹ ê· ì— ê°ì—¼ëœ ë™ë¬¼ì˜ ì†Œë³€ì´ ë¬¼ì´ë‚˜ í† ì–‘ì— ì˜¤ì—¼ë˜ê³ , ì—¬ê¸°ì— ì ë§‰ì´ë‚˜ ìƒì²˜ê°€ ë‹¿ìœ¼ë©´ ê°ì—¼ëœë‹¤. ì†Œë³€ì— ì§ì ‘ ì ‘ì´‰í•˜ê±°ë‚˜ ë¹„ë§ì„ í¡ì…, ì˜¤ì—¼ëœ ìŒì‹ì„ ë¨¹ì–´ë„ ê±¸ë¦´ ìˆ˜ ìˆë‹¤.   2) ìš°ë¦¬ë‚˜ë¼ì—ì„œ  ë†ì´Œê³¼ ë‚¨ë¶€ ì§€ì—­ ì— ë§ìœ¼ë©°, 8ì›” ì´ˆì—ì„œ 11ì›” ì‚¬ì´ì˜  ê°€ì„ ì—,  20~40ëŒ€ì˜ í™œë™ê¸° ì„±ì¸ ë‚¨ì ì—ê²Œì„œ í˜¸ë°œí•œë‹¤. ë”°ë¼ì„œ ì¶”ìˆ˜, ì„±ë¬˜, í›ˆë ¨ ë“±ì˜ ë³‘ë ¥ì„ ê°€ì§„ í™˜ìê°€ ë§ë‹¤. ë˜í•œ ë†ë¶€, ìˆ˜ì˜ì‚¬, í•˜ìˆ˜ë„ ë…¸ë™ì, ì•¼ì™¸í™œë™ì ë“±ì—ì„œ ì§ì—…ì  ë…¸ì¶œì´ ì¼ì–´ë‚˜ëŠ” ê²ƒë„ ê³ ë ¤í•´ì•¼í•œë‹¤.     í•´ë‹¹ ê· ì— ì˜í•´ ìƒê¸°ëŠ” ì§ˆë³‘ì„  Leptospirosis ë¼ í•˜ë©°, ì¤‘ì¦ ê°ì—¼ì˜ ê²½ìš° Weilâ€™s Diseaseë¼ ë¶€ë¥´ê¸°ë„ í•œë‹¤.       í•­ëª©   Leptospirosis   Weilâ€™s Disease       ì •ì˜   Leptospira interrogans ê°ì—¼ì— ì˜í•œ ì „ì‹ ì„±

</details>

<details>
<summary>2. 2522_5660_Vibrio spp..html (3/3)</summary>

ì œëª©: Vibrio spp.  2. Vibrio vulnificus     1) íŠ¹ì§•   (1) ìš´ë™ì„± æœ‰   (2) ì£¼ë¡œ ë°”ë‹·ë¬¼ì— ì¡´ì¬í•œë‹¤.     (3)  ìƒì²˜ì— ì ‘ì´‰ë˜ê±°ë‚˜ ì˜¤ì—¼ëœ í•´ì‚°ë¬¼ì„ ë¨¹ì„ ì‹œ ê°ì—¼ëœë‹¤.   (4) íŠ¹íˆ  í˜ˆí–‰ê°ì—¼ ì‹œ íŒ¨í˜ˆì¦ ì„ ì¼ìœ¼í‚¨ë‹¤.         2) ê³ ìœ„í—˜êµ°   : ë©´ì—­ì €í•˜ìë¥¼ ë¹„ë¡¯í•´  ë§Œì„± ê°„ì§ˆí™˜ì , ì•Œì½”ì˜¬ ì¤‘ë…ì. ê°„ ê¸°ëŠ¥ì´ ë–¨ì–´ì§„ ì‚¬ëŒì´ ê³ ìœ„í—˜êµ°ì¸ ì´ìœ ëŠ”, ê°„ì— ì €ì¥ëœ ì² ë¶„ì´ í˜ˆì•¡ìœ¼ë¡œ ë‚˜ì˜¤ê¸° ë–„ë¬¸ì´ë‹¤. ê· ì˜ ì¦ì‹ê³¼ì •ì— ì² ë¶„ì´ í•„ìˆ˜ì ì´ë‹¤.       3) ì„ìƒ ì¦ìƒ     (1) ê¸‰ì„± ë°œì—´, ì˜¤í•œ, êµ¬í†  ë“±ì„ ì¼ìœ¼í‚¤ë©° ìˆ˜ ì‹œê°„~1ì¼ ì´ë‚´ì— íŒ¨í˜ˆì„± ì‡¼í¬ë¥¼ ì¼ìœ¼í‚¨ë‹¤.   (2) ê´´ì‚¬ì„± ë³‘ë³€, ìˆ˜í¬, ìë°˜, ê´´ì‚¬ì„±ê·¼ë§‰ì—¼ ë“± soft tissueì— ê°ì—¼ë˜ì–´ ì¦ìƒì„ ë‚´ëŠ” ê²ƒì´ íŠ¹ì§•ì´ë‹¤. ì§„í–‰ì´ ë¹ ë¥´ê³  ì‚¬ë§ë¥ ì´ 50%ë¥¼ ë„˜ëŠ”ë‹¤.

</details>

<details>
<summary>3. 1757_4091_ìš”ë¡œê°ì—¼.html (3/5)</summary>

ì œëª©: ìš”ë¡œê°ì—¼  2. ì„ìƒì–‘ìƒ   ì—°ë ¹ê³¼ ê°ì—¼ ë¶€ìœ„ì— ë”°ë¼ ë‹¤ë¥´ê²Œ ë‚˜íƒ€ë‚œë‹¤.     1) Â  ì‹ ìƒì•„, ì˜ìœ ì•„: Â  ë¹„íŠ¹ì´ì  ì¦ìƒ   (1)  ì„¤ëª…ë˜ì§€ ì•ŠëŠ” ë°œì—´ : â‰¥ 38â„ƒ   (2)  ìˆ˜ìœ  ê°ì†Œ ,  ì†Œë³€ëŸ‰ ê°ì†Œ , ì„¤ì‚¬, êµ¬í†  Â ë“±   2) Â  ì—°ì¥ì•„: Â ëŒ€ë¶€ë¶„ Â  ì „í˜•ì ì¸ ì¦ìƒ   (1) ë°©ê´‘ì—¼:  ë¹ˆë‡¨ ,  ë°°ë‡¨ ê³¤ë€ , ìš”ì‹¤ê¸ˆ, í•˜ë³µë¶€ í†µì¦ Â (ë°œì—´ ë³´í†µ ì—†ìŒ)   (2) ê¸‰ì„± ì‹ ìš°ì‹ ì—¼:  ê³ ì—´  (â‰¥ 39â„ƒ),  ì˜†êµ¬ë¦¬ í†µì¦ , ë™í†µ ë° êµ¬í†    * ë°©ê´‘ì—¼ì—ì„œëŠ” ë°œì—´ê³¼ ê°™ì€ ì „ì‹  ì¦ìƒ, ì˜†êµ¬ë¦¬ ë¶€ìœ„ í†µì¦ì´ ì—†ê³ , ì‹ ìš°ì‹ ì—¼ì—ì„œëŠ” ë‘˜ ë‹¤ í¬í•¨í•˜ëŠ” ê²ƒì´ íŠ¹ì§•ì ì´ë‹¤.     3) íŒ¨í˜ˆì¦ìœ¼ë¡œ ì§„í–‰(urosepsis)   (1) ì³ì§,  ì†ë°œì´ ì°¨ê³  ì–¼ë£©ëœë£©í•¨ (ë§ì´ˆ perfusion ê°ì†Œ)   (2)  ë¹ˆë§¥ ,  ì €í˜ˆì••

</details>

<details>
<summary>4. 2747_5639_ì—¼ì¦ì˜ ì–‘ìƒ.html (3/3)</summary>

ì œëª©: ì—¼ì¦ì˜ ì–‘ìƒ  2. ë§Œì„± ì—¼ì¦ (chronic inflammation)   (1) ê°œìš”     â€¢  ìˆ˜ì£¼ì—ì„œ ìˆ˜ê°œì›” ì´ìƒ ì§€ì†ë˜ëŠ” ì—¼ì¦ ë°˜ì‘ìœ¼ë¡œ, ì—¼ì¦, ì¡°ì§ ì†ìƒ, ì¹˜ìœ  ì‹œë„ê°€ ë™ì‹œì— ë°˜ë³µë¨     (2) ì›ì¸     â€¢ ì§€ì†ê°ì—¼ (eg: ê²°í•µê· , ë°”ì´ëŸ¬ìŠ¤ ë“±)    â€¢ ë¯¸í•´ê²°ëœ ê¸‰ì„± ì—¼ì¦    â€¢ ìê°€ë©´ì—­ ì§ˆí™˜ìœ¼ë¡œ ì¸í•œ ì§€ì†ì  ë©´ì—­ ë° ì—¼ì¦ ë°˜ì‘    â€¢ ê·œì†Œì™€ ê°™ì€ ì™¸ì¸ì„± ë…ì„± ìê·¹ê³¼ ë™ë§¥ê²½í™”ì¦ê³¼ ê°™ì€ ë‚´ì¸ì„± ë…ì„± ìê·¹   (3) ì¡°ì§í•™ì  ì†Œê²¬     â€¢ ëŒ€ì‹ì„¸í¬, ë¦¼í”„êµ¬, í˜•ì§ˆì„¸í¬ ë“±ê³¼ ê°™ì€ ë‹¨í•µêµ¬ì˜ ì¹¨ìœ¤    â€¢ ì§€ì†ì ì¸ ì¡°ì§ ì†ìƒ ë° íŒŒê´´   â€¢ ì„¬ìœ ì•„ì„¸í¬ ì¦ì‹ê³¼ ì‹ ìƒí˜ˆê´€ í˜•ì„±ì„ í†µí•œ ì¡°ì§ ë³µêµ¬ ì‹œë„ â†’ ê²°ê³¼ì ìœ¼ë¡œ ì„¬ìœ í™”ë¡œ ì´ì–´ì§    Kidney with chronic inflammation and fibrosis, Wikipedia Commons     Reference: Robbins and Cotran, Pathologic Basis of Disease, 1

</details>

<details>
<summary>5. 2521_5678_Pseudomonas aeruginosa.html (2/2)</summary>

ì œëª©: Pseudomonas aeruginosa  2. ë³‘ë¦¬ ê¸°ì „   1) ìº¡ìŠì„ ë§Œë“¤ê³  Biofilmì„ í˜•ì„±í•˜ì—¬ ë©´ì—­ íšŒí”¼ ë° í•­ìƒì œ ë‚´ì„±ì„ ë‚˜íƒ€ë‚¸ë‹¤.   2) ë³‘ì›ì„± ì¸ì:   (1) Exotoxin A: EF-2 ì–µì œ â†’ ë‹¨ë°±ì§ˆ í•©ì„± ì–µì œ, ì„¸í¬ ë³€ì„±, ë©´ì—­ ê¸°ëŠ¥ ê°„ì„­, ì„¸í¬ ì‚¬ë©¸ ë“±   (2) Elastase, protease: ì¡°ì§íŒŒê´´, í˜ˆê´€ ì¹¨ë²”   (3) LPS: ë‚´ë…ì†Œ; ì—¼ì¦ ìœ ë°œ       ëŒ€í‘œì ì¸ ê¸°íšŒê°ì—¼ê· ì´ì ì›ë‚´ê°ì—¼ê· ì´ë‹¤.

</details>

<details>
<summary>6. 2525_5684_ëª¨ê¸° ë§¤ê°œ ê°ì—¼ë³‘.html (1/1)</summary>

ì œëª©: ëª¨ê¸° ë§¤ê°œ ê°ì—¼ë³‘  ë¶„ë¥˜ ë° ì¦ìƒ       ì†(genus)   ê´€ë ¨ ì§ˆë³‘ ë° ë¶„ë¥˜   ì¦ìƒ   ëŒ€í‘œ ìœ í–‰ ì§€ì—­         Anopheles   : ì–¼ë£©ë‚ ê°œëª¨ê¸°, í•™ì§ˆëª¨ê¸°   (ë°¤ì— í¡í˜ˆ)     ë§ë¼ë¦¬ì•„   ê¸°ìƒì¶©     ì£¼ê¸°ì ì¸ ë°œì—´ ë°œì‘ (ì˜¤í•œâ†’ê³ ì—´â†’ë°œí•œ)   ë‘í†µ, ê·¼ìœ¡í†µ, ê°„ë¹„ì¥ ë¹„ëŒ€, ë¹ˆí˜ˆ       ì•„í”„ë¦¬ì¹´   ì¸ë„           Aedes   : ìˆ²ëª¨ê¸°   (ë‚®ì— í¡í˜ˆ)     ë…ê¸°ì—´     ë°”ì´ëŸ¬ìŠ¤   (+)ssRNA     ë°œì—´, ê·¼ìœ¡í†µ, ì¶œí˜ˆ     ë™ë‚¨ì•„ì‹œì•„   ì¤‘ë‚¨ë¯¸         ì¹˜ì¿¤êµ°ì•¼ì—´   ê³ ì—´, ì‹¬í•œ ê´€ì ˆí†µ, ë‘í†µ, ê·¼ìœ¡í†µ   ì¸ë„, ë™ë‚¨ì•„ì‹œì•„       ì§€ì¹´ì—´   ë¯¸ì—´, ë°œì§„, ê²°ë§‰ì—¼   ì¤‘ë‚¨ë¯¸ ë° ë‚¨ë¯¸, ë™ë‚¨ì•„ì‹œì•„       í™©ì—´   ë°œì—´, ì˜¤í•œ, ë‘í†µ, ê·¼ìœ¡í†µ(íŠ¹íˆ ìš”í†µ), ì˜¤ì‹¬   ì•„í”„ë¦¬ì¹´ ì‚¬í•˜ë¼ ì´ë‚¨ ì§€ì—­, ë‚¨ì•„ë©”ë¦¬ì¹´ ì—´ëŒ€ ì§€ì—­         Culex   : ì§‘ëª¨ê¸°   (ë°¤ì— í¡í˜ˆ)     ì¼ë³¸ë‡Œì—¼     ë¬´ì¦ìƒ å¤š   ë‡Œì—¼ ì‹œ

</details>

<details>
<summary>7. 1643_3848_ì—¬í–‰ ê´€ë ¨ ë°”ì´ëŸ¬ìŠ¤ ê°ì—¼.html (1/6)</summary>

ì œëª©: ì—¬í–‰ ê´€ë ¨ ë°”ì´ëŸ¬ìŠ¤ ê°ì—¼  ë…ê¸°ì—´, ì¹˜ì¿¤êµ¬ë‹ˆì•¼ì—´, ì§€ì¹´ ë°”ì´ëŸ¬ìŠ¤ ê°ì—¼ì¦, í™©ì—´, ë©”ë¥´ìŠ¤ì— ëŒ€í•´ì„œ ë‹¤ë£¬ë‹¤. ì—¬í–‰ë ¥ê³¼ ì„ìƒì–‘ìƒì„ ë³´ê³  ê°€ëŠ¥ì„±ì´ ë†’ì€ ì§„ë‹¨ëª…ì„ ê³ ë¥´ëŠ” ë¬¸ì œê°€ ìì£¼ ì¶œì œëœë‹¤. ë¹„ìŠ·í•œ ì„ìƒì¦ìƒê³¼ ê° ì§ˆí™˜ë³„ ê°ë³„ í¬ì¸íŠ¸ë¥¼ ì˜ ê¸°ì–µí•´ë‘ì. ë…ê¸°ì—´, ì¹˜ì¿¤êµ¬ë‹ˆì•¼ì—´, ì§€ì¹´ ë°”ì´ëŸ¬ìŠ¤ ê°ì—¼ì¦ì€ ê³µí†µì ìœ¼ë¡œ ëª¨ê¸° ë§¤ê°œ ê°ì—¼ë³‘ì´ë©°, ë…ê¸°ì—´ì€ ëˆˆ ë’¤ìª½ ì•ˆêµ¬í†µ, ì¹˜ì¿¤êµ¬ë‹ˆì•¼ì—´ì€ ê´€ì ˆí†µ, ì§€ì¹´ ë°”ì´ëŸ¬ìŠ¤ ê°ì—¼ì¦ì€ ê²°ë§‰ì—¼ì´ ê°€ì¥ íŠ¹ì§•ì ì¸ ì¦ìƒì´ë‹¤. ì—¬í–‰ ê´€ë ¨ ê°ì—¼ì¦ì€ ì´ ì™¸ì—ë„ ë§ë¼ë¦¬ì•„, í™©ì—´, Aí˜• ê°„ì—¼, ì¥í‹°í‘¸ìŠ¤, ìˆ˜ë§‰ì•Œê· ìˆ˜ë§‰ì—¼, ê³µìˆ˜ë³‘, ì¼ë³¸ë‡Œì—¼, ì½œë ˆë¼ ë“± ë‹¤ì–‘í•œë°, ìœ í–‰í•˜ëŠ” ì§€ì—­ ì—¬í–‰ ì „ ì˜ˆë°©ì ‘ì¢…ì´ í•„ìš”í•œ ì§ˆí™˜ì´ ë§ê³  ë¬¸ì œì—ë„ ìì£¼ ì¶œì œë˜ë¯€ë¡œ  ì„±ì¸ ì˜ˆë°©ì ‘ì¢… Â ë‹¨ì›ê³¼ ì—°ê´€ì§€ì–´ ê³µë¶€í•˜ì.

</details>

<details>
<summary>8. 1640_3835_ë…¹ë†ê·  ê°ì—¼.html (3/5)</summary>

ì œëª©: ë…¹ë†ê·  ê°ì—¼  2. ì„ìƒì–‘ìƒ   1) ì „ì‹  ì¦ìƒ:  ë°œì—´ Â â†’ bacteremia,  septic shock Â ì§„í–‰ ê°€ëŠ¥     2) í˜¸í¡ê¸°: íë ´  (ê²°í•µ, ê¸°ê´€ì§€í™•ì¥ì¦ ë“± ë§Œì„± íì§ˆí™˜ì´ ìˆì„ ê²½ìš° í˜¸ë°œ)     3) Â  ê°ì—¼ì„± ì‹¬ë‚´ë§‰ì—¼     4) ëˆˆ:  ê°ë§‰ì—¼(keratitis), ì•ˆë‚´ì—¼(endophthalmitis)     5) í”¼ë¶€ & ì—°ì¡°ì§:  Ecthyma gangrenosum Â (í˜ˆì„± pustuleì´ ê´´ì‚¬ëœ í˜•íƒœ)     6) Â  ê¸°íƒ€: Bone & joint infection, UTI, endovascular infection, CNS infection

</details>

<details>
<summary>9. 1778_4160_ìœ„ì‹ë„ì—­ë¥˜ì§ˆí™˜.html (3/7)</summary>

ì œëª©: ìœ„ì‹ë„ì—­ë¥˜ì§ˆí™˜  2. ì„ìƒì–‘ìƒ   1) ì£¼í˜¸ì†Œ   (1)  ê°€ìŠ´ì“°ë¦¼ : m/c   â‘   ìœ„ì¹˜ : í‰ê³¨ ë’¤ìª½  â†’ íŒ”, ì–´ê¹¨, í„±, ë“±ìœ¼ë¡œ ë°©ì‚¬   â‘¡  ì•…í™”ìš”ì¸ : ì‹í›„,   ëˆ„ìš´ ìì„¸, ìƒˆë²½,  ë³µì•• ì¦ê°€(Valsalva maneuver ë“±)   â‘¢  ì™„í™”ìš”ì¸ : ë¬¼ ë§ˆì‹œê¸°,  ì œì‚°ì œ ë³µìš© ë“±   (2)  ê¸°ì¹¨ :  ì—­ë¥˜í•œ ìœ„ì‚° ë° ì´ë¡œ ì¸í•œ ìê·¹ì´ pharynx, respiratory epitheliumìœ¼ë¡œ ì „ë‹¬ë¨   * GERDëŠ” ìƒê¸°ë„ê¸°ì¹¨ì¦í›„êµ°, ì²œì‹ê³¼ ë”ë¶ˆì–´  ë§Œì„± ê¸°ì¹¨ì˜ 3ëŒ€ ì›ì¸  ì¤‘ í•˜ë‚˜ì´ë‹¤.     2) ê¸°íƒ€ ì¦ìƒ   (1)  ì‚° ì—­ë¥˜ ì¦ìƒ :  ìœ„ì•¡/ë‚´ìš©ë¬¼ì´ ì‹ë„/ì¸ë‘ë¡œ ì—­ë¥˜   â€¢ ì‹ ë§›, ì“´ë§›ì„ í˜¸ì†Œ   (2) í‰í†µ:  í˜‘ì‹¬ì¦ ê³¼ ê°ë³„ì´ í•„ìš” (ECG, ì‹¬ê·¼íš¨ì†Œ ë“±)   (3) ì‚¼í‚´ê³¤ë€: ë°˜ë³µëœ ì—¼ì¦ë°˜ì‘ìœ¼ë¡œ ì¸í•œ ì†Œí™”ì„± í˜‘ì°© ë°œìƒ ì‹œ ë‚˜íƒ€ë‚  ìˆ˜ ìˆìŒ

</details>

<details>
<summary>10. 1636_3826_ë°œì—´, ë¶ˆëª…ì—´.html (1/3)</summary>

ì œëª©: ë°œì—´, ë¶ˆëª…ì—´  ê°ì—¼ì„± ì§ˆí™˜ì—ì„œ ì£¼ë¡œ ë™ë°˜ë˜ëŠ” ì¦ìƒì¸ ë°œì—´ê³¼ ë¶ˆëª…ì—´ì— ëŒ€í•´ ë‹¤ë£¬ë‹¤. ì‹œí—˜ì— íŠ¹ë³„íˆ ë§ì´ ì¶œì œë˜ëŠ” ë¶€ë¶„ì€ ì•„ë‹ˆë‹¤. ë¶ˆëª…ì—´ í™˜ìì—ì„œ ë‹¤ìŒì— í•´ì•¼í•  ê²€ì‚¬, ì¡°ì¹˜ë¥¼ ë¬»ëŠ” ë¬¸ì œê°€ ì£¼ë¡œ ì¶œì œë˜ë‹ˆ ë¶ˆëª…ì—´ ì§„ë‹¨ì  ì ‘ê·¼ ì•Œê³ ë¦¬ì¦˜ì„ ê¼¼ê¼¼íˆ ìˆ™ì§€í•´ì•¼ í•œë‹¤. ì¶”ê°€ì ìœ¼ë¡œ ì™¸ê³¼ì´ë¡ ì˜  â€™ì‡¼í¬â€™ ë‹¨ì›ì˜ â€˜íŒ¨í˜ˆì„± ì‡¼í¬â€™ ë¶€ë¶„ì„ ì°¸ê³ í•˜ì—¬ sepsis syndromeì— ëŒ€í•´ì„œë„ ì˜ ì•Œì•„ë‘ì.

</details>

### ğŸ’¬ Answer
Okay, let's analyze the provided medical texts to identify infections similar to Dengue fever in terms of their transmission mechanism (mosquito-borne).

**Analysis and Classification**

Based on the provided texts, here's a breakdown of mosquito-borne diseases and related concepts:

*   **Mosquito-borne Diseases:** This is the key category. The texts explicitly mention several diseases transmitted by mosquitoes.
*   **Vector:** Mosquitoes act as vectors, transmitting pathogens (viruses, parasites) from one host to another.

**Detailed Breakdown of Relevant Information**

1.  **Text 6 (ëª¨ê¸° ë§¤ê°œ ê°ì—¼ë³‘ - Mosquito-borne Infections):** This text is the most directly relevant. It lists several mosquito-borne diseases, categorized by the *genus* of mosquito:

    *   *Anopheles* (ì–¼ë£©ë‚ ê°œëª¨ê¸°, í•™ì§ˆëª¨ê¸° - Malaria):  Malaria (Parasite)
        *   Symptoms: Periodic fever paroxysms (chills â†’ high fever â†’ sweating), headache, muscle pain, hepatosplenomegaly, anemia
        *   Regions: Africa, India
    *   *Aedes* (ìˆ²ëª¨ê¸° - Forest Mosquito):
        *   Dengue Fever (ë°”ì´ëŸ¬ìŠ¤ - Virus):
            *   Symptoms: Fever, muscle pain, bleeding
            *   Regions: Southeast Asia, Central and South America
        *   Chikungunya Fever (ë°”ì´ëŸ¬ìŠ¤ - Virus):
            *   Symptoms: High fever, severe joint pain, headache, muscle pain
            *   Regions: India, Southeast Asia
        *   Zika Fever (ë°”ì´ëŸ¬ìŠ¤ - Virus):
            *   Symptoms: Mild fever, rash, conjunctivitis
            *   Regions: Central and South America, Southeast Asia
        *   Yellow Fever (ë°”ì´ëŸ¬ìŠ¤ - Virus):
            *   Symptoms: Fever, chills, headache, muscle pain (especially back pain), nausea
            *   Regions: Sub-Saharan Africa, Tropical South America
    *   *Culex* (ì§‘ëª¨ê¸° - House Mosquito):
        *   Japanese Encephalitis (ë°”ì´ëŸ¬ìŠ¤ - Virus):
            *   Symptoms: Mostly asymptomatic; encephalitis can occur

2.  **Text 7 (ì—¬í–‰ ê´€ë ¨ ë°”ì´ëŸ¬ìŠ¤ ê°ì—¼ - Travel-related Viral Infections):** This text reinforces the importance of Dengue Fever, Chikungunya Fever, and Zika Virus infections as travel-related illnesses.  It highlights that they are all mosquito-borne and emphasizes the need to differentiate them based on specific symptoms (eye pain in Dengue, joint pain in Chikungunya, conjunctivitis in Zika).  It also mentions other travel-related infections, some of which (like Japanese Encephalitis) are mosquito-borne, while others (like Malaria, Yellow Fever, Aí˜• ê°„ì—¼, ì¥í‹°í‘¸ìŠ¤, ìˆ˜ë§‰ì•Œê· ìˆ˜ë§‰ì—¼, ê³µìˆ˜ë³‘, ì½œë ˆë¼) have different transmission routes.

**Answer to the Question**

Based on the provided texts, diseases transmitted by the same *type* of vector (mosquitoes) as Dengue Fever include:

*   **Chikungunya Fever:** Transmitted by *Aedes* mosquitoes.
*   **Zika Fever:** Transmitted by *Aedes* mosquitoes.
*   **Yellow Fever:** Transmitted by *Aedes* mosquitoes.
*   **Japanese Encephalitis:** Transmitted by *Culex* mosquitoes.
*   **Malaria:** Transmitted by *Anopheles* mosquitoes.

Therefore, the most directly similar diseases to Dengue fever, in terms of being mosquito-borne, are **Chikungunya Fever, Zika Fever, and Yellow Fever** since they are transmitted by the same genus of mosquito (*Aedes*). Malaria and Japanese Encephalitis are also mosquito-borne but transmitted by different mosquito genera.

---

## ğŸ” Query
ë¶ˆëª…ì—´ ì§„ë‹¨ ìˆœì„œë¥¼ ì„¤ëª…í•˜ì‹œì˜¤

### ğŸ“š Context

<details>
<summary>1. 1698_3968_ì„íšŒí™” ê±´ì—¼.html (4/5)</summary>

ì œëª©: ì„íšŒí™” ê±´ì—¼  3. ê°ë³„ì§„ë‹¨   1)  íšŒì „ê·¼ê°œíŒŒì—´ : ëŠ¥ë™ì  ê´€ì ˆìš´ë™ë²”ìœ„ ì œí•œ   2)  ìœ ì°©ì„± ê´€ì ˆë‚­ì—¼ : ëŠ¥ë™ì  & ìˆ˜ë™ì  ìš´ë™ë²”ìœ„ ì œí•œ   3)  ê²¬ê°‘ë¶€ íƒˆêµ¬ : ë³‘ì¸¡ ìœ„íŒ”ì´ ì™¸ì „, ì™¸íšŒì „ ë˜ì–´ ìˆê³  ë°˜ëŒ€ìª½ ì†ìœ¼ë¡œ ì¡ê³  ëª¸ì— ë¶™ì´ë ¤ê³  í•¨   4) í™”ë†ì„± ê´€ì ˆì—¼: ë°œì—´, leukocytosis ë“±

</details>

<details>
<summary>2. 1698_3967_íšŒì „ê·¼ê°œíŒŒì—´.html (5/6)</summary>

ì œëª©: íšŒì „ê·¼ê°œíŒŒì—´  4. ê°ë³„ì§„ë‹¨   1)  ì„íšŒí™” ê±´ì—¼ : ê´€ì ˆìš´ë™ ë²”ìœ„ëŠ” ë³´ì¡´   2)  ìœ ì°©ì„± ê´€ì ˆë‚­ì—¼ : ìˆ˜ë™ì  ìš´ë™ ë²”ìœ„ë„ ì œí•œ   3)  ê²¬ê°‘ë¶€ íƒˆêµ¬ : ë³‘ì¸¡ ìœ„íŒ”ì´ ì™¸ì „, ì™¸íšŒì „ ë˜ì–´ ìˆê³  ë°˜ëŒ€ìª½ ì†ìœ¼ë¡œ ì¡ê³  ëª¸ì— ë¶™ì´ë ¤ê³  í•¨   4) í™”ë†ì„± ê´€ì ˆì—¼: ë°œì—´, leukocytosis ë“±

</details>

<details>
<summary>3. 1636_3826_ë°œì—´, ë¶ˆëª…ì—´.html (1/3)</summary>

ì œëª©: ë°œì—´, ë¶ˆëª…ì—´  ê°ì—¼ì„± ì§ˆí™˜ì—ì„œ ì£¼ë¡œ ë™ë°˜ë˜ëŠ” ì¦ìƒì¸ ë°œì—´ê³¼ ë¶ˆëª…ì—´ì— ëŒ€í•´ ë‹¤ë£¬ë‹¤. ì‹œí—˜ì— íŠ¹ë³„íˆ ë§ì´ ì¶œì œë˜ëŠ” ë¶€ë¶„ì€ ì•„ë‹ˆë‹¤. ë¶ˆëª…ì—´ í™˜ìì—ì„œ ë‹¤ìŒì— í•´ì•¼í•  ê²€ì‚¬, ì¡°ì¹˜ë¥¼ ë¬»ëŠ” ë¬¸ì œê°€ ì£¼ë¡œ ì¶œì œë˜ë‹ˆ ë¶ˆëª…ì—´ ì§„ë‹¨ì  ì ‘ê·¼ ì•Œê³ ë¦¬ì¦˜ì„ ê¼¼ê¼¼íˆ ìˆ™ì§€í•´ì•¼ í•œë‹¤. ì¶”ê°€ì ìœ¼ë¡œ ì™¸ê³¼ì´ë¡ ì˜  â€™ì‡¼í¬â€™ ë‹¨ì›ì˜ â€˜íŒ¨í˜ˆì„± ì‡¼í¬â€™ ë¶€ë¶„ì„ ì°¸ê³ í•˜ì—¬ sepsis syndromeì— ëŒ€í•´ì„œë„ ì˜ ì•Œì•„ë‘ì.

</details>

<details>
<summary>4. 3442_5477_ê´€ì ˆì—¼ì˜ ê°œìš”.html (4/5)</summary>

ì œëª©: ê´€ì ˆì—¼ì˜ ê°œìš”  3. ì§„ë‹¨ ì•Œê³ ë¦¬ì¦˜

</details>

<details>
<summary>5. 1872_4389_ì§„ë‹¨ì„œ.html (1/1)</summary>

ì œëª©: ì§„ë‹¨ì„œ  ì§„ë‹¨ì„œ/ê²€ì•ˆì„œ/ì¦ëª…ì„œ : ì˜ì‚¬, ì¹˜ê³¼ì˜ì‚¬, í•œì˜ì‚¬   ì¶œìƒ/ì‚¬ë§/ì‚¬ì‚° ì¦ëª…ì„œ : ì˜ì‚¬, í•œì˜ì‚¬, ì¡°ì‚°ì‚¬       â€¢ ìµœì¢… ì§„ë£Œ( í‡´ì› )ë¶€í„°  48ì‹œê°„ ì´ë‚´ ì— ì‚¬ë§í•œ ê²½ìš°ì—ëŠ” ë‹¤ì‹œ ì§„ë£Œí•˜ì§€ ì•Šë”ë¼ë„ ì§„ë‹¨ì„œ/ì¦ëª…ì„œë¥¼ ë‚´ì¤„ ìˆ˜ ìˆë‹¤.   â€¢ í™˜ì ì‚¬ë§, ì˜ì‹ ì—†ì„ ì‹œ êµë¶€ ê°€ëŠ¥: ì§ê³„ì¡´ë¹„ì†, ë°°ìš°ì, ë°°ìš°ì ì§ê³„ì¡´ì† â†’ ëª¨ë‘ ì—†ìœ¼ë©´ í˜•ì œìë§¤           ìƒí•´ì§„ë‹¨ì„œ Â  ì¶”ê°€ ê¸°ì¬ì‚¬í•­     1) Â  ìƒí•´ì— ëŒ€í•œ ë‚´ìš© : ìƒí•´ì˜ ì›ì¸, ìƒí•´ì˜ ë¶€ìœ„ ë° ì •ë„, ìƒí•´ì— ëŒ€í•œ ì†Œê²¬   2) â€œ ì—¬ë¶€ â€ê°€ ë“¤ì–´ê°€ëŠ” ë‚´ìš© : ì…ì› í•„ìš” ì—¬ë¶€, ìˆ˜ìˆ  ì—¬ë¶€, í•©ë³‘ì¦ ë°œìƒ ê°€ëŠ¥ ì—¬ë¶€, í†µìƒ í™œë™ ê°€ëŠ¥ ì—¬ë¶€, ì‹ì‚¬ ê°€ëŠ¥ ì—¬ë¶€   3)  ì¹˜ë£Œê¸°ê°„       ì˜ë£Œë²• ì œ17ì¡°(ì§„ë‹¨ì„œ ë“±)   â‘  ì˜ë£Œì—…ì— ì¢…ì‚¬í•˜ê³  ì§ì ‘ ì§„ì°°í•˜ê±°ë‚˜ ê²€ì•ˆí•œ  ì˜ì‚¬ [ì´í•˜ ì´ í•­ì—ì„œëŠ” ê²€ì•ˆì„œì— í•œí•˜ì—¬ ê²€ì‹œì—…ë¬´ë¥¼ ë‹´ë‹¹í•˜ëŠ” êµ­ê°€ê¸°ê´€ì— ì¢…ì‚¬í•˜ëŠ” ì˜ì‚¬ë¥¼ í¬í•¨í•œë‹¤], Â ì¹˜ê³¼ì˜ì‚¬, í•œì˜ì‚¬ ê°€ ì•„ë‹ˆë©´ ì§„ë‹¨ì„œã†ê²€ì•ˆì„œã†ì¦ëª…ì„œ

</details>

<details>
<summary>6. 1799_4205_ìŠ¹ëª¨íŒ íƒˆì¶œ.html (4/5)</summary>

ì œëª©: ìŠ¹ëª¨íŒ íƒˆì¶œ  3. ì§„ë‹¨   ê²½í‰ë¶€ì‹¬ì´ˆìŒíŒŒ :  ìŠ¹ëª¨íŒ íƒˆì¶œ ë° MR ë™ë°˜ ì—¬ë¶€ í™•ì¸

</details>

<details>
<summary>7. 1922_4462_ë¦¼í”„ì¢….html (4/7)</summary>

ì œëª©: ë¦¼í”„ì¢…  3. ì§„ë‹¨   ë¦¼í”„ì ˆ ë¹„ëŒ€  ë‹¨ì›ì—ì„œë„ ê°•ì¡°ë˜ì—ˆë“¯ ë°˜ë“œì‹œ  ìƒê²€ ì´ í•„ìš”í•˜ë‹¤.     ì¡°ì§í•™ì  ì§„ë‹¨ì´ ë¶ˆê°€í•œ ë°”ëŠ˜í¡ì¸ì€ ì‹œí–‰í•´ì„œëŠ” ì•ˆëœë‹¤.

</details>

<details>
<summary>8. 1643_3846_ì¤‘ì¦ì—´ì„±í˜ˆì†ŒíŒê°ì†Œì¦í›„êµ°.html (3/5)</summary>

ì œëª©: ì¤‘ì¦ì—´ì„±í˜ˆì†ŒíŒê°ì†Œì¦í›„êµ°  2. ì„ìƒì–‘ìƒ ë° ê²€ì‚¬ì†Œê²¬   1) ì£¼í˜¸ì†Œ:  ë°œì—´   (ì ë³µê¸° 0~16ì¼)     2) ê¸°íƒ€ ì¦ìƒ ë° ì§•í›„   (1)  ë²Œë ˆì— ë¬¼ë¦° ìƒì²˜ :  ê°€í”¼ ì—†ìŒ  ( ì¯”ì¯”ê°€ë¬´ì‹œë³‘ ê³¼ì˜ ê°ë³„ì )     ë²Œë ˆì— ë¬¼ë¦° ê³¼ê±°ë ¥ê³¼ ìƒì²˜ê°€ ë¹¨ê°›ê²Œ ì£¼ì–´ì§ (ê°€í”¼ í˜•ì„± X)       (2) ì „ì‹ : ê·¼ìœ¡í†µ,  ê´€ì ˆí†µ ë“±   (3) ì†Œí™”ê¸°: ì˜¤ì‹¬/êµ¬í† , ì„¤ì‚¬,  ë³µí†µ   (4) CNS:  ë‘í†µ, ì–´ì§€ëŸ¬ì›€,  í˜¼ë™,   ì˜ì‹ì €í•˜   (5) ê¸°íƒ€: ê¸°ì¹¨, í˜¸í¡ê³¤ë€, ì‡ëª¸ì¶œí˜ˆ, ìë°˜ì¦, ë¦¼í”„ì ˆ ë¹„ëŒ€ ë“±     3) ê²€ì‚¬ì†Œê²¬   (1) CBC:  WBC â†“,  PLT â†“   *  ë°±í˜ˆêµ¬ê°ì†Œì¦ì´ ë™ë°˜ë˜ëŠ” ê°ì—¼ì§ˆí™˜ ì°¸ê³    (2) ê¸°íƒ€: AST/ALTâ†‘, LDHâ†‘, CKâ†‘,  hypoNa     4) ê²½ê³¼: 1ì£¼ ê°„ê²©ìœ¼ë¡œ  ë°œì—´ê¸° (1~7ì¼) â†’ ë‹¤ì¥ê¸°ë¶€ì „ê¸° (8~14ì¼) â†’ íšŒë³µê¸°  ìˆœìœ¼ë¡œ ì§„í–‰   (1) í•©ë³‘ì¦: ë‡Œìˆ˜ë§‰ì—¼, ë¶€ì •ë§¥, AKI, ì‹¬ê·¼ì—¼, ë‡Œì¶œí˜ˆ ë“±   (2) ì¤‘ì¦ì‹œ

</details>

<details>
<summary>9. 1925_4500_ìœ ëŸ‰-ìš©ëŸ‰ ê³¡ì„ .html (5/5)</summary>

ì œëª©: ìœ ëŸ‰-ìš©ëŸ‰ ê³¡ì„   4. ê¸°ë„ íì‡„         ê³ ì •í˜• ê¸°ë„íì‡„   í‰ê°• ì™¸ ë³€ì´í˜• ê¸°ë„íì‡„   í‰ê°• ë‚´ ë³€ì´í˜• ê¸°ë„íì‡„       í¡ê¸°/í˜¸ê¸° ëª¨ë‘ ê¸°ë¥˜ì œí•œ   í¡ê¸° ê¸°ë¥˜ì œí•œ   í˜¸ê¸° ê¸°ë¥˜ì œí•œ         ê¸°ê´€ì‚½ê´€ ìœ¡ì•„ì¢…   ì¥ê¸°ê°„ ê¸°ê´€ì‚½ê´€ í›„ í˜‘ì°©   ì‚°/ì—¼ê¸° í™”ìƒ í›„ ê¸°ë„ í˜‘ì°©     ê¸°ë„ ì™¸ ê°‘ìƒìƒ˜ì¢…ì–‘/ë¦¼í”„ì¢…   ì¥ê¸°ê°„ ê¸°ê´€ì‚½ê´€ í›„ í˜‘ì°©               Harrison 21e, pp.2133-2139   ëŒ€í•œê²°í•µ ë° í˜¸í¡ê¸°í•™íšŒ ê°€ì´ë“œë¼ì¸, 2016

</details>

<details>
<summary>10. 1636_3826_ë°œì—´, ë¶ˆëª…ì—´.html (2/3)</summary>

ì œëª©: ë°œì—´, ë¶ˆëª…ì—´  1. ë°œì—´(fever)   1) ì²´ì˜¨ (body temperature)   (1) Â  ì •ìƒ êµ¬ê°•ì²´ì˜¨: 36.8 Â± 0.4â„ƒ Â (6AM ê¸°ì¤€)   â‘  ì§ì¥ì²´ì˜¨ = êµ¬ê°•ì²´ì˜¨ + 0.4â„ƒ   â‘¡ 6AMì— ìµœì €, 4PMì— ìµœê³    â‘¢ ì—¬ì„±ì˜ ë°°ë€ê¸°ëŠ” ë°°ë€ 2ì£¼ ì „ë³´ë‹¤ 0.6â„ƒ ë†’ìŒ   (2) Â  ì²´ì˜¨ ì¡°ì ˆ   â‘  ì›ë¦¬: Hypothalamusì˜ thermoregulatory center ì—ì„œ ì§€ì •í•œ Â set point ì— ì²´ì˜¨ì„ ë§ì¶¤   â‘¡ ì²´ì˜¨ ë‚®ì¶”ëŠ” ì‘ìš©: ë•€, vasodilation   â‘¢ ì²´ì˜¨ ë†’ì´ëŠ” ì‘ìš©: Shivering, vasoconstriction     2) ë°œì—´ (fever)   (1) ì •ì˜: Â Normal daily variation ì´ìƒìœ¼ë¡œ ì²´ì˜¨ì´ ì˜¬ë¼ê°€ëŠ” í˜„ìƒ   â‘  ì„ìƒì ìœ¼ë¡œ êµ¬ê°• ì²´ì˜¨ì´  6AMì— â‰¥ 37.3â„ƒ ,  4PMì— â‰¥ 37.8â„ƒ   â‘¡ Hyperpyrexia: > 41.5â„ƒì˜ ê³ ì—´   (2) ì›ì¸   â‘   ê°ì—¼ (m/c)   â‘¡

</details>

### ğŸ’¬ Answer
Okay, based on the provided context, let's analyze the relevant information to explain the diagnostic approach to fever of unknown origin (FUO).

**1. Definition and Contextual Understanding of Fever and FUO:**

*   **Fever (ë°œì—´):**  The provided text defines fever as an elevation of body temperature beyond normal daily variation. Specific thresholds are given: oral temperature â‰¥ 37.3Â°C at 6 AM or â‰¥ 37.8Â°C at 4 PM. Hyperpyrexia is defined as >41.5Â°C. The most common cause of fever is infection. (Entries 8, 10)
*   **Fever of Unknown Origin (ë¶ˆëª…ì—´):**  While not explicitly defined in this snippet, the text emphasizes that FUO is a condition where the cause of fever remains elusive after initial evaluation.  The text highlights the importance of understanding the diagnostic approach to FUO. (Entry 3)

**2. Diagnostic Approach to FUO (ë¶ˆëª…ì—´ ì§„ë‹¨ì  ì ‘ê·¼):**

The provided text doesn't give the specific steps of the diagnostic algorithm, but it strongly emphasizes the *need* to know it:

*   "ë¶ˆëª…ì—´ í™˜ìì—ì„œ ë‹¤ìŒì— í•´ì•¼í•  ê²€ì‚¬, ì¡°ì¹˜ë¥¼ ë¬»ëŠ” ë¬¸ì œê°€ ì£¼ë¡œ ì¶œì œë˜ë‹ˆ ë¶ˆëª…ì—´ ì§„ë‹¨ì  ì ‘ê·¼ ì•Œê³ ë¦¬ì¦˜ì„ ê¼¼ê¼¼íˆ ìˆ™ì§€í•´ì•¼ í•œë‹¤."  This translates to: "Questions about the next tests and actions to take in a patient with FUO are frequently asked, so you must carefully learn the diagnostic approach algorithm for FUO." (Entry 3)

**Therefore, the answer to your question is that the text does not provide the specific steps of the FUO diagnostic algorithm, but it strongly emphasizes that you must learn it.**

**3. Relevant Information and Considerations (Related Concepts and Differentials):**

Although the exact algorithm isn't given, the surrounding context provides clues about what might be involved in the differential diagnosis and evaluation of FUO, as well as related conditions that can present with fever:

*   **Infectious Diseases (ê°ì—¼ì„± ì§ˆí™˜):**  Fever is a common symptom of infectious diseases.  The text mentions sepsis syndrome (referencing the "septic shock" section in the surgical overview) as a possible consideration. (Entry 3)
*   **Specific Infectious Diseases to Consider:**
    *   **ì¤‘ì¦ì—´ì„±í˜ˆì†ŒíŒê°ì†Œì¦í›„êµ° (Severe Fever with Thrombocytopenia Syndrome - SFTS):** This is explicitly mentioned and characterized by fever, potential tick bite history, muscle/joint pain, GI symptoms, CNS symptoms (headache, confusion), and characteristic lab findings (leukopenia, thrombocytopenia, elevated liver enzymes).  The text highlights the importance of distinguishing it from Tsutsugamushi disease (ê°€í”¼ ìœ ë¬´). (Entry 8)
*   **Inflammatory/Rheumatologic Conditions:**  While not explicitly stated in the context of FUO, the inclusion of "ê´€ì ˆì—¼ì˜ ê°œìš”" (Overview of Arthritis) suggests that inflammatory conditions causing fever might be a consideration. (Entry 4)
*   **Malignancy:** The mention of "ë¦¼í”„ì¢…" (Lymphoma) and "ìœ ëŸ‰-ìš©ëŸ‰ ê³¡ì„ " (Flow-Volume Loop) with mention of airway obstruction due to lymphoma suggests malignancy as a possible consideration in FUO, particularly if there's lymphadenopathy or airway involvement. (Entries 7, 9)
*   **Non-infectious causes of fever:** The text does not mention specific non-infectious causes of fever other than malignancy and inflammatory/rheumatologic conditions.

**4.  Diagnostic Tools and Procedures (Implied from Context):**

*   **Laboratory Tests:**  The discussion of SFTS highlights the importance of CBC (complete blood count - looking for leukopenia and thrombocytopenia) and liver function tests (AST/ALT).  The mention of "leukocytosis" in the differential diagnosis of "í™”ë†ì„± ê´€ì ˆì—¼" (pyogenic arthritis) suggests that WBC count is a key test. (Entries 1, 2, 8)
*   **Microbiological Studies:** Given the emphasis on infection, cultures (blood, urine, etc.) would likely be part of the FUO workup.
*   **Imaging:** The text doesn't directly mention imaging in the context of FUO, but it would likely be utilized to look for sources of infection or malignancy (e.g., chest X-ray, CT scan).
*   **Biopsy:** The strong emphasis on biopsy for diagnosing lymphoma suggests that tissue sampling might be necessary in some FUO cases, especially if lymphadenopathy is present. (Entry 7)
*   **Echocardiography:** The mention of echocardiography in the context of mitral valve prolapse implies that cardiac causes of fever (e.g., endocarditis) should be considered and evaluated if clinically indicated. (Entry 6)

**In summary, while the provided text doesn't give the specific FUO diagnostic algorithm, it sets the stage by:**

1.  Defining fever.
2.  Emphasizing the *importance* of knowing the FUO diagnostic algorithm.
3.  Hinting at potential diagnostic considerations through examples of infectious diseases, inflammatory conditions, and malignancies.
4.  Implying the use of laboratory tests, imaging, and potentially biopsy in the workup.

To fully answer your question, you would need to consult dedicated resources on FUO, focusing on the step-by-step diagnostic approach.

---

## ğŸ” Query
íŒ¨í˜ˆì¦ì˜ ì •ì˜ì™€ ì¹˜ë£Œ ì ‘ê·¼ë²•ì€?

### ğŸ“š Context

<details>
<summary>1. 1636_4736_íŒ¨í˜ˆì¦.html (5/5)</summary>

ì œëª©: íŒ¨í˜ˆì¦  4. ì¹˜ë£Œ   1)  ìˆ˜ì•¡ì†Œìƒìˆ  (fluid resuscitation)   (1) 1 st  line:  IV crystalloid   â‘  0.9% ì‹ì—¼ìˆ˜ (normal saline, N/S)   â‘¡ Balanced crystalloid (ë§ê±°ì –ì‚°, í•˜íŠ¸ë§Œìš©ì•¡, í”Œë¼ìŠ¤ë§ˆ ì†”ë£¨ì…˜ A ë“±)   â‘¢ ë‘˜ ì¤‘ ì–´ëŠ ì œì œê°€ ìš°ì›”í•œì§€ì— ëŒ€í•œ ëª…í™•í•œ ê·¼ê±°ëŠ” ì—†ìŒ   (2) 2 nd  line: IV colloid  (20% albumin ë“±)   (3) 3 rd  line: ìŠ¹ì••ì œ (vasopressor)   â‘    IV norepinephrine :  ìŠ¹ì••ì œ ì¤‘ 1 st  line (ì‹¬ê·¼ìˆ˜ì¶•ë ¥â†‘, í˜ˆê´€ìˆ˜ì¶•â†‘)   â‘¡ IV vasopressin:  Norepinephrine íˆ¬ì—¬ëŸ‰ì„ ì¤„ì´ê¸° ìœ„í•œ ëª©ì ìœ¼ë¡œ ì¶”ê°€ ê°€ëŠ¥   (4) 4 th  line: ê°•ì‹¬ì œ(inotropic agent) - dobutamine   (5) 5 th  line: Corticosteroid - hydroco

</details>

<details>
<summary>2. 1657_3890_ì €ì¹¼ìŠ˜í˜ˆì¦.html (5/5)</summary>

ì œëª©: ì €ì¹¼ìŠ˜í˜ˆì¦  4. ì¹˜ë£Œ   ê¸‰ì„±/ë§Œì„± ì—¬ë¶€, ì¤‘ì¦ë„, ë™ë°˜ í•©ë³‘ì¦(ë°œì‘, laryngospasm ë“±) ì—¬ë¶€ì— ë”°ë¼ ì¹˜ë£Œê°€ ë‹¬ë¼ì§„ë‹¤.     1) ê¸‰ì„±   (1)  IV calcium gluconate Â +  5DW or N/S   (2) HypoMg ë™ë°˜ ì‹œ: Mg ë³´ì¶©     2) ë§Œì„±   (1) Hypoparathyroidism: Â  Ca ë³´ì¶© Â +  vit. D   (2) Vit. D ê²°í•: ë³´ì¶©   (3) Thiazide: Hypercalciuria ì˜ˆë°© (í˜ˆì¤‘ Ca 2+ â†‘)   *  Hypercalcemic crisis ì—ì„œëŠ” loop diureticì¸ furosemideë¥¼ ì‚¬ìš©í–ˆë˜ ê²ƒê³¼ ëŒ€ì¡°ëœë‹¤.       Harrison 21e, pp.3185-3190   ì´ë¯¸ì§€:  Trousseauâ€™s sign

</details>

<details>
<summary>3. 1912_4464_ë¹ˆí˜ˆì˜ ì ‘ê·¼.html (8/8)</summary>

ì œëª©: ë¹ˆí˜ˆì˜ ì ‘ê·¼  7. ë¹ˆí˜ˆ ì¹˜ë£Œ ì›ì¹™   1) ìˆ˜í˜ˆ: ë¬´ì¡°ê±´ ìˆ˜í˜ˆí•˜ì§€ ì•Šìœ¼ë©°,  ìƒí™©ì— ë”°ë¼ íŒë‹¨í•¨   (1) Hb < 7 ì´ë”ë¼ë„, ë§Œì„±ì ì¸ IDAì¸ ê²½ìš°ì—ëŠ” ì‘ê¸‰ì´ ì•„ë‹ˆë¯€ë¡œ ìˆ˜í˜ˆ X   (2) Hb = 10 ì´ë”ë¼ë„, ê±´ê°•í•œ ë‚¨ìê°€ Hb 16 â†’ 10ìœ¼ë¡œ ê¸‰ê²©íˆ ê°ì†Œí•˜ë©´ ì‘ê¸‰ìœ¼ë¡œ ê°„ì£¼í•  ìˆ˜ ìˆìŒ     2) ìˆ˜í˜ˆ ì „ì— ì›ì¸ ê°ë³„ í›„  ì›ì¸ êµì •ì´ ë¨¼ì €         Harrison 21e, pp.431-438

</details>

<details>
<summary>4. 1656_3900_ì´ìƒì§€ì§ˆí˜ˆì¦ì˜ ì¹˜ë£Œ.html (3/5)</summary>

ì œëª©: ì´ìƒì§€ì§ˆí˜ˆì¦ì˜ ì¹˜ë£Œ  2. ì¹˜ë£Œ ëª©í‘œ   1)  ì‹¬í˜ˆê´€ì§ˆí™˜ ì£¼ìš” ìœ„í—˜ì¸ì (LDL ì œì™¸)   * ìˆ˜ì¹˜ê¹Œì§€  ëª¨ë‘ ì™¸ì›Œì•¼ í•œë‹¤.     ìœ„í—˜ì¸ì:  í•´ë‹¹ ì‹œ +1     (1) ì—°ë ¹   F â‰¥ 55     M â‰¥ 45     (2) ê³ í˜ˆì••   â‰¥ 140/90 mmHg or í•­ê³ í˜ˆì••ì œ ë³µìš© ì¤‘       (3) í¡ì—°   í˜„ì¬ í¡ì—° (ê³¼ê±° í¡ì—°ë ¥ì€ X)       (4) Low HDL-C   < 40 mg/dL       (5) ê´€ìƒë™ë§¥ì§ˆí™˜ ì¡°ê¸°ë°œë³‘ ê°€ì¡±ë ¥ (ë¶€ëª¨, í˜•ì œìë§¤ ì¤‘)   ë‚¨ì„± ê°€ì¡±ì˜ ë°œë³‘ ë‚˜ì´ < 55     ì—¬ì„± ê°€ì¡±ì˜ ë°œë³‘ ë‚˜ì´ < 65   ë°©ì–´ì¸ì:  í•´ë‹¹ ì‹œ -1     High HDL-C   â‰¥ 60 mg/dL         2)  Risk groupì— ë”°ë¥¸ LDL/non-HDL-C goal   * ìˆ˜ì¹˜ê¹Œì§€  ëª¨ë‘ ì™¸ì›Œì•¼ í•œë‹¤.       ìœ„í—˜êµ°   ì˜ˆì‹œ ì§ˆí™˜   LDL-C   non-HDL-C       ì´ˆê³ ìœ„í—˜êµ°     1) ê´€ìƒë™ë§¥ì§ˆí™˜   2) FH +

</details>

<details>
<summary>5. 1636_4736_íŒ¨í˜ˆì¦.html (1/5)</summary>

ì œëª©: íŒ¨í˜ˆì¦  : Sepsis       êµ­ì‹œì—ì„œ ê°ì—¼ì§ˆí™˜ì˜ ë¹„ì¤‘ì€ ë§¤ë…„ 15% ê°€ê¹Œì´ ë˜ë©°, ì´ ì¤‘ ì¤‘ì¦ ê°ì—¼ë„ ë§ì´ ì¶œì œëœë‹¤. ë”°ë¼ì„œ íŒ¨í˜ˆì¦ì„ ì˜ ì´í•´í•˜ëŠ” ê²ƒì´ êµ­ì‹œì— ìˆì–´ì„œ, ë” ë‚˜ì•„ê°€ ì¢‹ì€ ì˜ì‚¬ê°€ ë˜ëŠ” ë° ìˆì–´ì„œ ë§¤ìš° ì¤‘ìš”í•˜ë‹¤ëŠ” ê²ƒì€ ì•„ë¬´ë¦¬ ê°•ì¡°í•´ë„ ì§€ë‚˜ì¹˜ì§€ ì•Šë‹¤. ë³¸ ë‹¨ì›ì€ íŒ¨í˜ˆì¦ê³¼ íŒ¨í˜ˆì„± ì‡¼í¬ì˜ ê¸°ë³¸ì ì¸ ê°œë…ê³¼ ì§„ë‹¨ì  ì ‘ê·¼, ì¹˜ë£Œë¥¼ ë‹¤ë£¨ê³  ìˆìœ¼ë©°, íŒ¨í˜ˆì¦ì´ ì•„ë‹ˆë”ë¼ë„ ê°ì—¼ì§ˆí™˜ ì „ë°˜ì— ëŒ€í•œ ë‚´ìš©ì„ ì•„ìš°ë¥´ê³  ìˆë‹¤.

</details>

<details>
<summary>6. 1654_3885_ë‹¹ë‡¨ì˜ ì¹˜ë£Œ.html (2/7)</summary>

ì œëª©: ë‹¹ë‡¨ì˜ ì¹˜ë£Œ  1. ê°œìš”   1) ë‹¹ë‡¨ ì¹˜ë£Œì˜ ëª©ì    (1) Hyperglycemia ê´€ë ¨ ì¦ìƒ ì¡°ì ˆ   (2) ë‹¹ë‡¨ì— ì˜í•´ ë°œìƒí•  ìˆ˜ ìˆëŠ” í•©ë³‘ì¦ ì˜ˆë°©  (ë¯¸ì„¸í˜ˆê´€í•©ë³‘ì¦, ëŒ€í˜ˆê´€í•©ë³‘ì¦ ë“±)     2) ì¹˜ë£Œ monitoring ì§€í‘œ:   HbA1c   (í˜ˆìƒ‰ì†Œì˜ ë‹¹í™” ì •ë„)   â€¢  ì§€ë‚œ 3ê°œì›”  ê°„ì˜ ë‹¹ ì¡°ì ˆ ì •ë„ë¥¼ ì•Œ ìˆ˜ ìˆìŒ (ì í˜ˆêµ¬ ìˆ˜ëª…ì´ 3ê°œì›”)     4) HbA1c ëª©í‘œ:  ì¼ë°˜ì ì¸ ì„±ì¸ ê¸°ì¤€   (1)  T1DM :  HbA1c  <  7.0%   (2)  T2DM :  HbA1c  <  6.5%   * ì¤‘ì¦ì €í˜ˆë‹¹ ê³¼ê±°ë ¥, ì§„í–‰ëœ í˜ˆê´€í•©ë³‘ì¦, ì§§ì€ ê¸°ëŒ€ ì—¬ëª…, ê³ ë ¹ ë“± ë‹¤ì–‘í•œ ìš”ì†Œë¥¼ ê³ ë ¤í•´ ëª©í‘œë¥¼ ê°œë³„í™”í•´ì•¼ í•œë‹¤.     5) HbA1c ì™¸ ëª©í‘œ:  ì‹¬í˜ˆê´€ì§ˆí™˜ì˜ risk factorë¥¼ í•¨ê»˜ ì¡°ì ˆí•´ì•¼ í•¨   * LDL ëª©í‘œì¹˜ëŠ” ì´í›„ ì´ìƒì§€ì§ˆí˜ˆì¦ íŒŒíŠ¸ì—ì„œë„ ì¤‘ìš”í•˜ê²Œ ë‹¤ë£¨ê³  ë¬¸ì œì—ì„œ ì¶œì œë˜ëŠ” ë¶€ë¶„ì´ë‹¤. ì´ì™¸ ìˆ˜ì¹˜ëŠ” êµ­ì‹œì—ëŠ” ì¶œì œë˜ì§€ ì•Šìœ¼ë‚˜ ì‹¤ì œ ì„ìƒ ì§„ë£Œì—ì„œëŠ”

</details>

<details>
<summary>7. 1657_3889_ê³ ì¹¼ìŠ˜í˜ˆì¦.html (5/6)</summary>

ì œëª©: ê³ ì¹¼ìŠ˜í˜ˆì¦  4. ì¹˜ë£Œ   1) ì¹˜ë£Œì˜ ì¢…ë¥˜     ê³µí†µ ì•½ë¬¼     (1)  ìˆ˜ì•¡ ì¹˜ë£Œ (N/S ë“±): ê°€ì¥ ì¤‘ìš”  (hyperCa í™˜ìëŠ” ëŒ€ë¶€ë¶„ íƒˆìˆ˜ ìƒíƒœ)   (2)   ìˆ˜ì•¡ + furosemide:  Ca 2+  ë°°ì„¤ ì´‰ì§„ (forced diuresis)   * ThiazideëŠ” Ca sparing, furosemideëŠ” ë°˜ëŒ€ ì‘ìš©ì„ í•˜ëŠ” ê²ƒì„ ê¸°ì–µí•˜ë©´ ì¢‹ë‹¤.   (3) ê³¨í¡ìˆ˜ ì–µì œ (antiresorptive)   â‘  Calcitonin:  ê°€ì¥ ë¹¨ë¦¬ ì‘ìš© (ìˆ˜ ì‹œê°„ ë‚´)   â‘¡ Bisphosphonate(pamidronate, zolendronate):  1~2ì¼ í›„ íš¨ê³¼ ì‹œì‘   â‘¢ Denosumab:  ê°€ì¥ ê°•ë ¥í•¨     íŠ¹ìˆ˜ ìƒí™©ì—ì„œ ì‚¬ìš©í•˜ëŠ” ì•½ë¬¼     (1) Glucocorticoid   â‘  ê³¨ì „ì´ ì¢…ì–‘ì— íš¨ê³¼: Leukemia, lymphoma ë“±   â‘¡ Vit. D ì¦ê°€ê°€ ì›ì¸ì¸ ì§ˆí™˜ì— íš¨ê³¼: Vit. D ì¤‘ë…, ìœ¡ì•„ì¢…ì„± ì§ˆí™˜ ë“±   (2) íˆ¬ì„: ì‹ ë¶€

</details>

<details>
<summary>8. 1758_4067_ì €í˜ˆë‹¹.html (4/4)</summary>

ì œëª©: ì €í˜ˆë‹¹  3. ì²˜ì¹˜   1) ì›ì¸ ì¹˜ë£Œ: Â ì €í˜ˆë‹¹ì¦ì„ ì¼ìœ¼í‚¤ëŠ” 1ì°¨ì  ì§ˆí™˜ ì¹˜ë£Œ   2) ì‹ ìƒì•„ ë° ì˜ì•„ì˜ ê¸‰ì„± ì €í˜ˆë‹¹ì¦: Â  10% í¬ë„ë‹¹ ìš©ì•¡ ì •ì£¼ Â â†’ í˜¸ì „ ì—†ì„ ì‹œ  hydrocortisone , GH, glucagon   3) ê³ ì¸ìŠë¦°í˜ˆì¦ì— ì˜í•œ ì €í˜ˆë‹¹: ê²½êµ¬ diazoxide, octreotide íˆ¬ì—¬         í™ì°½ì˜ ì†Œì•„ê³¼í•™ 12e, pp.1168-1171

</details>

<details>
<summary>9. 1656_3900_ì´ìƒì§€ì§ˆí˜ˆì¦ì˜ ì¹˜ë£Œ.html (5/5)</summary>

ì œëª©: ì´ìƒì§€ì§ˆí˜ˆì¦ì˜ ì¹˜ë£Œ  4. ì¹˜ë£Œì  ìƒí™œìŠµê´€ ê°œì„  (therapeutic lifestyle change, TLC)   1) ì‹ì‚¬ìš”ë²•, ì²´ì¤‘ ì¡°ì ˆ   (1) ì ì • ì²´ì¤‘ ìœ ì§€: í†µê³¡ë¬¼, ì±„ì†Œë¥˜, ìƒì„ ë¥˜ í’ë¶€í•œ ì‹ì‚¬íŒ¨í„´ ìœ ì§€   (2) ì´ ì§€ë°© ì„­ì·¨ëŸ‰, ì´ íƒ„ìˆ˜í™”ë¬¼ ì„­ì·¨ëŸ‰ ì ì • ìˆ˜ì¤€ìœ¼ë¡œ ê³¼ë‹¤í•˜ì§€ ì•Šê²Œ ì¡°ì ˆ   (3) í¬í™”ì§€ë°©ì‚° ì„­ì·¨ëŸ‰(< ì´ ì—ë„ˆì§€ 7%), ë‹¹ë¥˜ ì„­ì·¨ëŸ‰(< 10-20%) ì œí•œ   (4) ê³ ì½œë ˆìŠ¤í…Œë¡¤í˜ˆì¦: ì½œë ˆìŠ¤í…Œë¡¤ ì„­ì·¨ëŸ‰ ì œí•œ   (5) ì‹ì´ì„¬ìœ  ì¶©ë¶„íˆ ì„­ì·¨   (6) ì•Œì½”ì˜¬ ì œí•œ     2) ìš´ë™ìš”ë²•   (1) ì‹ ì²´ í™œë™ëŸ‰ ì¦ê°€   (2) ìœ ì‚°ì†Œ ìš´ë™: ì¤‘ë“±ë„ ê°•ë„, 30ë¶„ ì´ìƒ, ì£¼ 4~6íšŒ ì‹œí–‰   (3) ì €í•­ì„± ìš´ë™: ì£¼ 2íšŒ ì´ìƒ ì‹œí–‰     3) ê¸ˆì—°:  ê°•ë ¥íˆ ê¶Œê³          Harrison 21e, pp.3148-3150   í•œêµ­ì§€ì§ˆÂ·ë™ë§¥ê²½í™”í•™íšŒ ê°€ì´ë“œë¼ì¸, 2022

</details>

<details>
<summary>10. 1661_3905_ì „ì‹ ê²½í™”ì¦.html (6/8)</summary>

ì œëª©: ì „ì‹ ê²½í™”ì¦  5. ì¹˜ë£Œ   ì™„ì¹˜ê°€ ì–´ë ¤ìš°ë©°, ê° í•©ë³‘ì¦ì´ ë°œìƒí•  ë•Œë§ˆë‹¤ ì´ì— ë§ì¶”ì–´ ì¹˜ë£Œë¥¼ ì‹œí–‰í•œë‹¤.     1) ë ˆì´ë…¸ í˜„ìƒ   (1) ë¹„ì•½ë¬¼ì¹˜ë£Œ: ë”°ëœ»í•˜ê²Œ ì†ê°€ë½ ë³´í˜¸í•˜ê¸°, ê¸°íƒ€ ìœ ë°œ ì¸ì ë…¸ì¶œ ìµœì†Œí™”, ê¸ˆì—° ë° ê´€ë ¨ ì•½ì œ íšŒí”¼ ë“±   (2) ì•½ë¬¼ì¹˜ë£Œ:  í˜ˆê´€ í™•ì¥ì œ   â‘   DHP-CCB : Nifedipine, amlodipine ë“±   â‘¡ ê¸°íƒ€: Sildenafil(PDE5 inhibitor), iloprost(prostaglandin analogue)     2) ê¸°íƒ€ í•©ë³‘ì¦   (1) í”¼ë¶€ ê²½í™”: Methotrexate, mycophenolate mofetil, rituximab ë“±   (2) ILD: Cyclophosphamide, mycophenolate mofetil, nintedanib   (3) PAH: Sildenafil + bosentan(endothelin receptor antagonist), prostaglandin analogue ë“±   (4)

</details>

### ğŸ’¬ Answer
Okay, let's break down the definition and treatment approaches for sepsis, drawing from the provided context and expanding on related concepts in medicine.

**I. Definition of Sepsis (and Septic Shock)**

Based on the provided texts, the definition of sepsis is not explicitly detailed, but we can infer crucial aspects:

*   **Sepsis is a severe infection.** Text #5 emphasizes the importance of understanding sepsis within the broader context of infectious diseases. It highlights that sepsis is a severe manifestation of infection.
*   **Sepsis involves a dysregulated host response.** While not explicitly stated, modern definitions of sepsis (Sepsis-3 consensus) emphasize that it's not just infection, but the *body's* overwhelming and dysregulated response to that infection that causes organ dysfunction.
*   **Septic shock** is a subset of sepsis with circulatory and cellular/metabolic dysfunction.
*   **Organ Dysfunction**: Implied by the need for interventions like vasopressors and inotropes, sepsis leads to organ dysfunction.

**Expanded Definition (Based on Sepsis-3):**

Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection.  Septic shock is a subset of sepsis in which particularly profound circulatory, cellular, and metabolic abnormalities are associated with a greater risk of mortality than with sepsis alone. Clinically, septic shock is defined as sepsis that requires vasopressors to maintain a mean arterial pressure (MAP) of 65 mm Hg or greater and has a serum lactate level greater than 2 mmol/L (18 mg/dL) despite adequate fluid resuscitation.

**II. Treatment of Sepsis**

The provided text #1 focuses on the initial resuscitation and hemodynamic support aspects of sepsis treatment.  Here's a breakdown:

1.  **Fluid Resuscitation:**
    *   **First-line:** IV Crystalloids
        *   Examples: 0.9% Normal Saline (N/S), Balanced Crystalloids (Lactated Ringer's, Hartmann's solution, Plasma-Lyte A)
        *   Important Note:  The text states there's no definitive evidence that one crystalloid is superior to another.
    *   **Second-line:** IV Colloid (e.g., 20% Albumin)
    *   **Rationale:**  Sepsis often causes vasodilation and increased capillary permeability, leading to intravascular volume depletion.  Fluid resuscitation aims to restore adequate circulating volume and tissue perfusion.

2.  **Vasopressors:**
    *   **First-line:** IV Norepinephrine (Levophed)
        *   Mechanism: Increases myocardial contractility and vasoconstriction.
    *   **Second-line:** IV Vasopressin
        *   Use:  Can be added to reduce the required dose of norepinephrine.  Vasopressin acts on V1 receptors to cause vasoconstriction.
    *   **Rationale:**  If fluid resuscitation alone is insufficient to maintain adequate blood pressure, vasopressors are used to increase systemic vascular resistance and improve blood pressure.

3.  **Inotropic Agents:**
    *   Example: Dobutamine
    *   Use: Considered if there is evidence of myocardial dysfunction (e.g., low cardiac output despite adequate preload and afterload).
    *   Rationale: Dobutamine is a beta-1 adrenergic agonist that increases myocardial contractility and cardiac output.

4.  **Corticosteroids:**
    *   Example: Hydrocortisone
    *   Use: May be considered in patients with refractory septic shock (i.e., those who remain hypotensive despite adequate fluid resuscitation and vasopressor support).
    *   Rationale: Corticosteroids can help restore vascular responsiveness to vasopressors and may have anti-inflammatory effects.

**Important Considerations & Additional Treatment Aspects (Beyond the Text):**

*   **Early Recognition and Source Control:** The most crucial aspect of sepsis management, missing from the provided texts, is early recognition and prompt source control. Identify the source of infection (e.g., pneumonia, UTI, abscess) and implement measures to control it (e.g., antibiotics, drainage of abscess).
*   **Antibiotics:** Prompt administration of broad-spectrum antibiotics is essential.  The choice of antibiotics should be based on the suspected source of infection and local resistance patterns.  De-escalation to more narrow-spectrum antibiotics is performed when culture results are available.
*   **Oxygenation and Ventilation:**  Support respiratory function.  This may involve supplemental oxygen, non-invasive ventilation (e.g., CPAP, BiPAP), or mechanical ventilation.
*   **Monitoring:** Continuous monitoring of vital signs, oxygen saturation, urine output, and other relevant parameters is crucial.
*   **Lactate Monitoring:** Serial lactate measurements are important to assess the adequacy of resuscitation and tissue perfusion.  A decreasing lactate level indicates improved perfusion.
*   **Glucose Control:**  Hyperglycemia is common in sepsis and can worsen outcomes.  Maintain blood glucose levels within a target range (e.g., 140-180 mg/dL).
*   **Supportive Care:**  Address other organ dysfunction as needed (e.g., renal replacement therapy for acute kidney injury, blood transfusions for anemia, DVT prophylaxis).
*   **Nutrition:** Provide adequate nutritional support to meet the patient's metabolic demands.
*   **Prevention:** Prevention strategies include appropriate hand hygiene, vaccination, and infection control measures.

**In summary:** Sepsis is a life-threatening condition requiring a multi-faceted approach. The provided text highlights the importance of fluid resuscitation and vasopressor support. However, it is critical to remember that early recognition, source control, and prompt antibiotic administration are also essential components of effective sepsis management. The treatment is tailored to the individual patient and the specific source and severity of the infection.

---

## ğŸ” Query
ë°œì—´ì˜ ë³‘íƒœìƒë¦¬ ê³¼ì •ì„ ì„¤ëª…í•˜ì‹œì˜¤

### ğŸ“š Context

<details>
<summary>1. 1654_3883_ë‹¹ë‡¨ì˜ ê°œìš”ì™€ ë³‘íƒœìƒë¦¬.html (1/4)</summary>

ì œëª©: ë‹¹ë‡¨ì˜ ê°œìš”ì™€ ë³‘íƒœìƒë¦¬  ë‹¹ë‡¨ì˜ ë¶„ë¥˜ì™€ ë³‘íƒœ ìƒë¦¬ì— ëŒ€í•´ ë‹¤ë£¬ íŒŒíŠ¸ì´ë‹¤. ì§ì ‘ ì¶œì œë˜ì§€ëŠ” ì•Šìœ¼ë‚˜ ì´í›„ ë‚´ìš©ì˜ ì´í•´ì— ë„ì›€ì´ ë˜ëŠ” ë‚´ìš©ìœ¼ë¡œ, ì„¸ì„¸í•œ ë‚´ìš©ì„ ëª¨ë‘ ì•”ê¸°í•  í•„ìš”ëŠ” ì—†ë‹¤.

</details>

<details>
<summary>2. 1867_4342_í™”ìƒ.html (4/6)</summary>

ì œëª©: í™”ìƒ  3. í™”ìƒì˜ ë³‘íƒœìƒë¦¬   1) ì¤‘ì¦ í™”ìƒì˜ ì •ì˜   (1) > 20% TBSA(total body surface area) (ì„±ì¸) / > 40% TBSA (ì†Œì•„)   (2) ì£¼ìš” ì™¸ìƒ ë™ë°˜   (3) í¡ì…, í™”í•™, ê³ ì•• ì „ê¸° í™”ìƒ     2) ë³‘íƒœìƒë¦¬   (1) Hypermetabolism   â‘  ì¹´í…Œì½œì•„ë¯¼, ì½”í‹°ì†”, ê¸€ë£¨ì¹´ê³¤, ë„íŒŒë¯¼ ë¶„ë¹„â†‘   â‘¡ ì´í™”ì‘ìš©(glycolysis, proteolysis, lipolysis) ì´‰ì§„   (2) ì—¼ì¦ê³¼ ë¶€ì¢…: Â Capillary permeabilityâ†‘, edema   (3) ì‹¬í˜ˆê´€ê³„ ë³€í™”: í˜ˆì¥ëŸ‰â†“, ë§ì´ˆ í˜ˆê´€ ì €í•­â†‘, ì‹¬ê·¼ìˆ˜ì¶•ë ¥â†“, ì‹¬ë°•ì¶œëŸ‰â†“   (4) ì‹ ì¥í˜ˆë¥˜â†“: í˜ˆì¥ëŸ‰â†“, ì•ˆì§€ì˜¤í…ì‹ , ì•Œë„ìŠ¤í…Œë¡ , ë°”ì†Œí”„ë ˆì‹  ë“±   (5) ì†Œí™”ê¸°ê´€: ì ë§‰ ìœ„ì¶•, í¡ìˆ˜ ì¥ì• , intestinal permeabilityâ†‘   (6) ë©´ì—­ ì–µì œ

</details>

<details>
<summary>3. 1868_4327_ë±€ë¬¼ë¦¼ê³¼ ë™ë¬¼ë¬¼ë¦¼.html (2/7)</summary>

ì œëª©: ë±€ë¬¼ë¦¼ê³¼ ë™ë¬¼ë¬¼ë¦¼  1. ë³‘íƒœìƒë¦¬   1) ë‹¨ë°±ì§ˆ ê°€ìˆ˜ë¶„í•´ íš¨ì†Œ ì„±ë¶„: êµ­ì†Œ ì¡°ì§ ê´´ì‚¬, í˜ˆì•¡ì‘ê³ ì¥ì• , ì¥ê¸°ë¶€ì „   2) ì¶œí˜ˆë…: í˜ˆê´€ ëˆ„ì¶œ â†’ ì²´ì•¡ ì´ë™, ì¶œí˜ˆ   3) ì‹¬ê·¼ì–µì œì¸ì: Cardiac output â†“   4) Bradykinin: í˜ˆê´€í™•ì¥   5) ì‹ ê²½ë…: ì‹ ê²½ê·¼ì ‘í•©ë¶€ ì°¨ë‹¨

</details>

<details>
<summary>4. 1778_4161_ë§ë¡œë¦¬-ë°”ì´ìŠ¤ ì¦í›„êµ°.html (2/6)</summary>

ì œëª©: ë§ë¡œë¦¬-ë°”ì´ìŠ¤ ì¦í›„êµ°  1. ê°œìš”   1) ë³‘íƒœìƒë¦¬   (1)   ì‹¬í•œ êµ¬í†    â†’ ê¸‰ê²©í•œ ë³µì•• ìƒìŠ¹   (2) ì´ë¡œ ì¸í•´ ì‹ë„ì˜ submucosal layerê¹Œì§€ í¬í•¨í•˜ëŠ”  ì—´ìƒ ë°œìƒ   (3) ì—´ìƒìœ¼ë¡œ ì¸í•œ  ì¶œí˜ˆ  â†’  í† í˜ˆ     2) ì—­í•™:  ì£¼ë¡œ  ìŒì£¼  í›„ í”íˆ ë°œìƒ

</details>

<details>
<summary>5. 1778_5473_ì‹¬í™” 1. ì‹ë„ì•”ì˜ ë³‘ê¸°ì™€ ì¹˜ë£Œ.html (2/4)</summary>

ì œëª©: ì‹¬í™” 1. ì‹ë„ì•”ì˜ ë³‘ê¸°ì™€ ì¹˜ë£Œ  1. ë³‘ê¸° ì„¤ì •         T stage     Tis   Mucosaì˜ basement membrane ì´í•˜ì— êµ­í•œëœ high-grade dysplasia       T1   Submucosaê¹Œì§€ ì¹¨ë²”       T1a   Mucosaì˜ lamina propria ë˜ëŠ” muscularis mucosa ì¹¨ë²”       T1b   Submucosa ì¹¨ë²”       T2   Proper muscle ì¹¨ë²”       T3   Adventitia ì¹¨ë²”       T4   ì£¼ë³€ êµ¬ì¡°ë¬¼ ì¹¨ë²”       T4a   Pleura, pericardium, azygos v., diaphragm, peritoneum ì¹¨ë²”       T4b   ê¸°íƒ€ êµ¬ì¡°ë¬¼ ì¹¨ë²” (ex. aorta, vertebral body, airway ë“±)     N stage     N0   LN ì „ì´ ì—†ìŒ       N1   LN ì „ì´ 1~2ê°œ       N2   LN ì „ì´ 3~6ê°œ

</details>

<details>
<summary>6. 1910_4458_ì¢…ì–‘ìš©í•´ì¦í›„êµ°.html (2/4)</summary>

ì œëª©: ì¢…ì–‘ìš©í•´ì¦í›„êµ°  1. ê°œìš”   1) ë³‘íƒœìƒë¦¬   (1)  CTx Â /  RTx Â ì´í›„ ì¢…ì–‘ ì„¸í¬ê°€ ì‚¬ë©¸ â†’  ì„¸í¬ ë‚´ ë¬¼ì§ˆë“¤ì´ í˜ˆì•¡ìœ¼ë¡œ ìœ ë¦¬ë¨   â‘  Hyperuricemia:  ì„¸í¬ ë‚´ nucleic acidê°€ uric acidë¡œ ë³€í™˜ë¨   â‘¡ Hyperkalemia:  K + ëŠ” ì„¸í¬ ë‚´ì— í›¨ì”¬ ë§ìŒ   â‘¢ Hyperphosphatemia:  ì„¸í¬ë§‰, DNA, ATP ë“±ì˜ í˜•íƒœë¡œ ì„¸í¬ ë‚´ì— ë§ìŒ   â‘£ Hypocalcemia:  í˜ˆì¤‘ phosphateê°€ ë§ì•„ì ¸ calcium phosphate í˜•íƒœë¡œ ê²°ì •í™”ë˜ì–´ í˜ˆì¤‘ Ca 2+ Â ê°ì†Œ   (2) Uric acid crystalì´ ì‹ ì¥ì— ì¹¨ì°© â†’  ìš”ì‚°ì—¼ì½©íŒ¥ë³‘ì¦ (uric acid nephropathy) ìœ ë°œ   * ì£¼ë¡œ tubule, collecting duct, medullaì— ì¹¨ì°©ë˜ë©°, calcium phosphate crystal ë˜í•œ ì‹ ì¥ì— ì¹¨ì°©ë˜ì–´ AKIë¥¼ ìœ ë°œí•œë‹¤.   (3) ì „í•´ì§ˆ ë¶ˆê· í˜•ìœ¼ë¡œ ì¸í•´  ì‹¬ì •ì§€  ê°€ëŠ¥

</details>

<details>
<summary>7. 1740_4032_ë‹¤íƒœì„ì‹ .html (5/5)</summary>

ì œëª©: ë‹¤íƒœì„ì‹   4. ìŒìƒì•„ê°„ ìˆ˜í˜ˆ ì¦í›„êµ° (twin-to-twin transfusion syndrome, TTTS)   1) ì •ì˜: Â Monochorionic twinê°„  í˜ˆê´€ anastomosis ê°€ ë°œìƒí•´ í•œ íƒœì•„ì—ì„œ ë‹¤ë¥¸ íƒœì•„ë¡œ ìˆ˜í˜ˆë˜ëŠ” í˜„ìƒ     2) ê²€ì‚¬ì†Œê²¬: ì´ˆìŒíŒŒ   (1) Donor twin:  ì–‘ìˆ˜ê³¼ì†Œì¦(oligohydramnios) , anemia, growth restriction   (2) Recipient twin:  ì–‘ìˆ˜ê³¼ë‹¤ì¦(hydramnios) , polycythemia, heart failure, ìˆ˜ì¢…(hydrops)   * ì–‘ìˆ˜ëŸ‰ì€ íƒœì•„ì˜ renal flowì— ì˜í•´ í° ì˜í–¥ì„ ë°›ëŠ”ë‹¤. ì–‘ìˆ˜ëŸ‰ì— ëŒ€í•œ ì¶”ê°€ì  ë‚´ìš©ì€  â€˜ì–‘ìˆ˜, íƒœë°˜, íƒ¯ì¤„ ì´ìƒâ€™ Â ì°¸ê³      3) ì§„ë‹¨ ê¸°ì¤€:  MCDA ì´ë©´ì„œ í•œ íƒœì•„ëŠ” hydramnios(ìµœëŒ€ì–‘ìˆ˜ìˆ˜ì§ê¹Šì´ >8cm), ë‹¤ë¥¸ í•œ íƒœì•„ëŠ” oligohydramnios(ìµœëŒ€ì–‘ìˆ˜ìˆ˜ì§ê¹Šì´<2cm)     4) ì²˜ì¹˜:  íƒœì•„ê²½

</details>

<details>
<summary>8. 1844_4316_ìœ ë°©ì•”.html (8/8)</summary>

ì œëª©: ìœ ë°©ì•”  7. ë³‘ê¸°(staging)   * ìì„¸í•œ ë³‘ê¸°ëŠ” êµ­ì‹œ ë¬¸ì œë¥¼ í‘¸ëŠ”ë° ì•Œì§€ ì•Šì•„ë„ í° ìƒê´€ì´ ì—†ë‹¤. ì•„ë˜ëŠ” clinical staging ê¸°ì¤€ìœ¼ë¡œ, í•„ìš”í•œ ì‚¬ëŒë§Œ ì°¸ê³ í•˜ë©´ ëœë‹¤ .     1) T stage     T1   í¬ê¸° â‰¤ 2cm       T2   2cm < í¬ê¸° â‰¤ 5cm       T3   í¬ê¸° > 5cm       T4   í‰ë²½ or í”¼ë¶€ ì¹¨ë²” / ì—¼ì¦ì„± ìœ ë°©ì•”           2) N stage     N0   LN ì „ì´ ì—†ìŒ       N1   ë™ì¸¡ level I, II axillary LN ì „ì´ + ì´‰ì§„ì‹œ ì›€ì§ì„       N2     ë™ì¸¡ level I, II axillary LN ì „ì´ + ì´‰ì§„ì‹œ ê³ ì •ë¨   ë™ì¸¡ internal mammary LN ì „ì´         N3     ë™ì¸¡ level I, II axillary LN ì „ì´ + ë™ì¸¡ internal mammary LN ì „ì´   ë™ì¸¡ infraclavicular LN ì „ì´   ë™ì¸¡ sup

</details>

<details>
<summary>9. 1743_4049_ìê¶ì™¸ ì„ì‹ .html (3/6)</summary>

ì œëª©: ìê¶ì™¸ ì„ì‹   2. ë³‘íƒœìƒë¦¬   ë¹„ì •ìƒ ìœ„ì¹˜ì— ì°©ìƒ â†’  Î²-hCG ë¶„ë¹„ ì‹œì‘ â†’  ê·¸ëŸ¬ë‚˜  ì •ìƒ ì„ì‹ ë§Œí¼ Î²-hCGê°€ ìƒìŠ¹í•˜ì§€ ì•ŠìŒ Â â†’ ê³„ì† ìë¼ë‹¤ê°€ ìœ ì‚° ë˜ëŠ”  ë‚œê´€ íŒŒì—´ (tubal rupture) ë°œìƒ

</details>

<details>
<summary>10. 1910_4458_ì¢…ì–‘ìš©í•´ì¦í›„êµ°.html (1/4)</summary>

ì œëª©: ì¢…ì–‘ìš©í•´ì¦í›„êµ°  : Tumor lysis syndrome, TLS       í•­ì•”ì¹˜ë£Œë¥¼ ë°›ì€ í›„ ì¢…ì–‘ ì„¸í¬ê°€ ì‚¬ë©¸í•˜ë©° ì„¸í¬ ë‚´ë¶€ì˜ ë¬¼ì§ˆë“¤ì´ í˜ˆì•¡ ë‚´ë¡œ ëŒ€ëŸ‰ ìŸì•„ì ¸ ë“¤ì–´ì˜¤ëŠ” ì§ˆí™˜ì´ë‹¤. ì„ìƒì–‘ìƒì´ ë¹„íŠ¹ì´ì ì´ë¼ê³  ë³¼ ìˆ˜ ìˆìœ¼ë‚˜ í•­ì•”í™”í•™ìš”ë²•ì´ë¼ëŠ” ëª…í™•í•œ ê³¼ê±°ë ¥ì´ ì£¼ì–´ì§€ê¸° ë•Œë¬¸ì— ë‹¤ì†Œ ì‰½ê²Œ ì¶”ì •ì§„ë‹¨ì„ ì¡ì„ ìˆ˜ ìˆë‹¤. ì¹˜ë£Œë¿ë§Œ ì•„ë‹ˆë¼ ë³‘íƒœìƒë¦¬ì— ëŒ€í•´ì„œë„ ì¶œì œëœ ì ì´ ìˆìœ¼ë¯€ë¡œ ê¼¼ê¼¼íˆ ì•Œì•„ë‘ë„ë¡ í•˜ì. ì°¸ê³ ë¡œ ì‹ ì¥ íŒŒíŠ¸ì˜  íš¡ë¬¸ê·¼ìœµí•´ì¦(rhabdomyolysis) ê³¼ ëª‡ëª‡ ì„ìƒì–‘ìƒ ë° lab ì†Œê²¬ì´ ë¹„ìŠ·í•˜ë¯€ë¡œ ê°™ì´ ê³µë¶€í•˜ê¸°ë¥¼ ê¶Œí•œë‹¤.

</details>

### ğŸ’¬ Answer
The provided text excerpts do not directly address the pathophysiology of fever. However, several entries discuss disease mechanisms and systemic responses that can indirectly relate to fever development. Here's a breakdown of relevant categories and how they contribute to the potential for fever:

**1. Inflammation and Systemic Inflammatory Response (SIRS):**

*   **í™”ìƒ (Burns):**  Burns trigger a hypermetabolic state driven by increased catecholamines, cortisol, glucagon, and dopamine.  Critically, they also induce inflammation with increased capillary permeability and edema. This inflammatory response is a key component of SIRS.  The body's attempt to repair the burn injury releases inflammatory mediators (cytokines) that can directly influence the hypothalamic set point for body temperature, leading to fever.  The extent of the burn (TBSA) directly correlates with the severity of the inflammatory response.

*   **ë±€ë¬¼ë¦¼ê³¼ ë™ë¬¼ë¬¼ë¦¼ (Snake and Animal Bites):** Snake venom contains enzymes that cause tissue necrosis, coagulopathy, and organ failure.  These effects release cellular debris and trigger an inflammatory cascade, potentially leading to fever. Furthermore, some snake venoms contain bradykinin, a vasodilator, which can contribute to systemic effects.

*   **ì¢…ì–‘ìš©í•´ì¦í›„êµ° (Tumor Lysis Syndrome - TLS):** This is a prime example of how cellular breakdown can lead to systemic issues.  The rapid lysis of tumor cells releases intracellular contents (uric acid, potassium, phosphate) into the bloodstream. This leads to electrolyte imbalances and uric acid nephropathy.  The massive release of intracellular components can also trigger a significant inflammatory response, contributing to fever. The text specifically mentions that TLS has been a topic on exams, including its pathophysiology.

**2. Infection (Implied Risk):**

*   While not explicitly stated, compromised skin barriers from burns or animal bites increase the risk of bacterial infection. Infection is a very common cause of fever.

**3. Immune Suppression:**

*   **í™”ìƒ (Burns):** The text mentions that burns can cause immune suppression.  This impaired immunity makes the patient more susceptible to infections, which are a major cause of fever.

**4. Endocrine/Metabolic Changes:**

*   **í™”ìƒ (Burns):** The hypermetabolic state in burns, mediated by stress hormones, can indirectly affect thermoregulation. While not a direct cause of fever, it contributes to the overall physiological stress on the body.

**How these relate to Fever Pathophysiology:**

Fever is typically triggered by pyrogens (fever-inducing substances). These can be exogenous (e.g., bacterial toxins like lipopolysaccharide (LPS)) or endogenous (e.g., cytokines like IL-1, IL-6, TNF-alpha). These pyrogens act on the hypothalamus, the body's thermoregulatory center, to raise the body temperature set point.

The inflammatory conditions described in the excerpts (burns, snake bites, TLS) can all lead to the release of endogenous pyrogens (cytokines). Tissue damage, necrosis, and cell lysis all stimulate the immune system to produce these inflammatory mediators.

**In summary,** while the provided texts don't directly detail the fever pathway, they illustrate conditions that can trigger the release of inflammatory mediators (cytokines). These cytokines are key endogenous pyrogens that act on the hypothalamus to increase the body temperature set point, resulting in fever. The severity of the fever is often proportional to the degree of inflammation and the underlying trigger.

---

## ğŸ” Query
ì‹¬ë¶€ì „ìœ¼ë¡œ ì…ì›í•œ í™˜ìì˜ ì´ˆê¸° í‰ê°€ í•­ëª©ì€?

### ğŸ“š Context

<details>
<summary>1. 1888_4435_ì •ì‹ ê³¼ì  í‰ê°€.html (3/6)</summary>

ì œëª©: ì •ì‹ ê³¼ì  í‰ê°€  2. ì •ì‹ ì§ˆí™˜ë³„ ì¸¡ì •ì²™ë„       ì •ì‹ ì§ˆí™˜ êµ°   ì¸¡ì • ì²™ë„       ì •ì‹ ë³‘ì  ì§ˆí™˜     â€¢ ê°„í¸ì •ì‹ ìƒíƒœ í‰ì •ì²™ë„(brief psychiatric rating scale, BPRS)   â€¢  ì–‘ì„± ë° ìŒì„±ì¦í›„êµ° ì²™ë„ (positive and negative symptom scale, PANSS)   â€¢ ì–‘ì„±ì¦ìƒ í‰ê°€ì²™ë„(scale for the assessment of positive symptoms, SAPS)   â€¢ ìŒì„±ì¦ìƒ í‰ê°€ì²™ë„(scale for the assessment of negative symptoms, SANS)         ê¸°ë¶„ì¥ì•      â€¢  ë²¡ ìš°ìš¸ì²™ë„ (Beck depression inventory, BDI)   â€¢ í•´ë°€í„´ ìš°ìš¸ì¦ í‰ê°€ì²™ë„(Hamilton rating scale for depression, HAM-D)         ë¶ˆì•ˆì¥ì•      â€¢ í•´ë°€í„´ ë¶ˆì•ˆ í‰ê°€ì²™ë„(Hamilton anxiety rating scale,

</details>

<details>
<summary>2. 1862_4330_ì„ íƒì  ìˆ˜ìˆ ì— ëŒ€í•œ ë°˜ì‘.html (3/4)</summary>

ì œëª©: ì„ íƒì  ìˆ˜ìˆ ì— ëŒ€í•œ ë°˜ì‘  2. ì˜ì–‘ìƒíƒœ í‰ê°€ ì§€í‘œ   1) í‰ê°€ ì§€í‘œ   (1) ë³‘ë ¥ì²­ì·¨   â‘  ì¦ìƒ: ì²´ì¤‘ê°ì†Œ, ì‹ìš•ë¶€ì§„, í¡ìˆ˜ì¥ì•  ê´€ë ¨ ì¦ìƒ ë“±   â‘¡ ì˜ì–‘ê²°í•ì˜ ìœ„í—˜ìš”ì¸: ì‚¬íšŒê²½ì œì  ìƒíƒœ, ìœ„ì¥ê´€ ìˆ˜ìˆ ë ¥, ìŒì£¼/í¡ì—°ë ¥   (2) ì‹ ì²´ì§„ì°°: ì²´ì¤‘, í‘œì¤€ì²´ì¤‘, ì²´ì§ˆëŸ‰ì§€ìˆ˜, í”¼ë¶€ì£¼ë¦„ ë‘ê»˜ ë“± ì¸¡ì •   (3) ê¸°íƒ€ ì‹ ì²´ ì§€í‘œ ì¸¡ì •: ê°„ì ‘ ì—´ëŸ‰, ì‚°ì†Œì†Œëª¨ëŸ‰, í˜¸í¡ì§€ìˆ˜, ì§ˆì†Œí‰í˜• ë“±   (4) í˜ˆì•¡ê²€ì‚¬:  ì•Œë¶€ë¯¼ ,  í”„ë¦¬ì•Œë¶€ë¯¼ ,  íŠ¸ëœìŠ¤í˜ë¦° Â ë“± lab ê²°ê³¼   (5) ì˜ìƒê²€ì‚¬: DXA ì´ìš©í•˜ì—¬ ì œì§€ë°©ì²´ì¤‘(lean body mass) ì¸¡ì •, US/CT ë“±     2) ìƒí™”í•™ì  ì¸¡ì •:  Protein status ë°˜ì˜   (1)  ì•Œë¶€ë¯¼(albumin)   â‘  Â  ìˆ˜ìˆ  í›„ íšŒë³µì˜ ì˜ˆí›„ì¸ì:  ì‹ ì²´ ê³„ì¸¡ë³´ë‹¤ ë” ë‚˜ì€ ì˜ˆí›„ì¸ì   â‘¡ ì•Œë¶€ë¯¼â†“: Negative catabolic state   â‘¢ í•©ì„±ì„ ìœ„í•´ì„œ ìƒë‹¹í•œ ì—ë„ˆì§€ê°€ í•„ìš”í•˜ë©° ì—¼ì¦ì— ì˜í•´ ì–µì œ ë¨   â‘£ < 3 g/dL:

</details>

<details>
<summary>3. 1797_5451_ì‹¬í™” 1. ì‹¬ì´ˆìŒíŒŒ.html (1/9)</summary>

ì œëª©: ì‹¬í™” 1. ì‹¬ì´ˆìŒíŒŒ  : Echocardiography       ì‹¬ì¥ê³¼ í˜ˆì•¡ì€ ë§¤ ìˆœê°„ ì›€ì§ì´ê³  ìˆë‹¤. ë”°ë¼ì„œ ì‹¬ì¥ì§ˆí™˜ì˜ ì˜ìƒê²€ì‚¬ì— ìˆì–´ì„œ ì‹œê°„í•´ìƒë„ëŠ” ë§¤ìš° ì¤‘ìš”í•˜ë©°, ì´ ë•Œë¬¸ì— ì‹¬ì´ˆìŒíŒŒëŠ” ì‹¬ì¥ì§ˆí™˜ì˜ í‰ê°€ì— ìˆì–´ í•„ìˆ˜ì ì¸ ë„êµ¬ê°€ ë˜ì—ˆë‹¤. êµ­ì‹œì—ì„œë„ ê·¸ ì¤‘ìš”ë„ê°€ ì ì  ê°•ì¡°ë˜ê³  ìˆë‹¤. ì˜ˆì „ì—ëŠ” ì¢Œì‹¬ì‹¤ë°•ì¶œë¥ ì²˜ëŸ¼ ì§ê´€ì ìœ¼ë¡œ ì´í•´í•˜ê¸° ì‰¬ìš´ ì§€í‘œë¥¼ ì§€ë¬¸ì— ì œì‹œí•˜ê±°ë‚˜ ì‹¬ì´ˆìŒíŒŒ ì‚¬ì§„ì—ì„œ pericardial effusion ì •ë„ë¥¼ ì°¾ì•„ë‚´ëŠ” ì •ë„ë§Œ ìš”êµ¬í–ˆë‹¤ë©´, ìµœê·¼ì—ëŠ” í•™ìƒ ìˆ˜ì¤€ì—ì„œ ê¸°ëŒ€í•˜ê¸° ì–´ë ¤ìš´ ì„¸ë¶€ì ì¸ ì§€í‘œë‚˜ ë³µì¡í•œ window ì‚¬ì§„ì„ ì œì‹œí•˜ëŠ” ê²½ìš°ë„ ìƒê²¨ë‚˜ê³  ìˆë‹¤. í•˜ì§€ë§Œ ì—¬ì „íˆ êµ­ì‹œ ë¬¸ì œë¥¼ ë‹¨ìˆœíˆ ë§ì¶”ëŠ” ìˆ˜ì¤€ì—ì„œëŠ” ' ì‹¬í˜ˆê´€ê³„ ê²€ì‚¬ ' ë‹¨ì›ì˜ 'ì‹¬ì´ˆìŒíŒŒ' ë¶€ë¶„ê³¼ ê° ê°œë³„ ì§ˆí™˜ ë‹¨ì›ì˜ ë‚´ìš©ë§Œ ì•Œì•„ë„ ì¶©ë¶„í•  ê²ƒìœ¼ë¡œ ë³´ì¸ë‹¤. ë³¸ ë‹¨ì›ì€ í•™ìƒ ìˆ˜ì¤€ë³´ë‹¤ëŠ” ë°”ì´íƒˆ ê³¼ ì „ê³µì˜ ì…ë¬¸ ìˆ˜ì¤€ì˜ ë‚´ìš©ì´ë‹¤. 'ì•„ì§ ì¶œì œë˜ì§€ ì•Šì•˜ìœ¼ë‚˜ ì¶œì œë  ì§€ë„ ëª¨ë¥´ëŠ”' ì‹¬ì´ˆìŒíŒŒì˜ ì„¸ë¶€ì  ë‚´ìš©ì— ëŒ€í•´ì„œ ëŒ€ë¹„í•˜ê³  ì‹¶ê±°ë‚˜,

</details>

<details>
<summary>4. 1801_4190_ì‹¬ê·¼ì—¼.html (4/7)</summary>

ì œëª©: ì‹¬ê·¼ì—¼  3. ê²€ì‚¬ì†Œê²¬   1) CXR:  ì •ìƒ or pleural effusion, cardiomegaly ê´€ì°° ê°€ëŠ¥     2) ECG:  ë¹„íŠ¹ì´ì    â€¢  ST elevation : MIë‚˜ pericarditisì™€ ìœ ì‚¬í•œ ì–‘ìƒ ê°€ëŠ¥     3) í˜ˆì•¡ê²€ì‚¬   (1)  BNP ìƒìŠ¹ : HF  ë™ë°˜ ì‹œì‚¬   (2)  ì‹¬ê·¼ íš¨ì†Œ ìƒìŠ¹ : Troponin, CK-MB  ë“± (ì‹¬ê·¼ì„¸í¬ ì†ìƒì´ ì›ì¸ â†’  MIì™€ ê°ë³„ í•„ìš” )     * ê¸‰ì„± í‰í†µ, ST elevation, ì‹¬ê·¼ íš¨ì†Œ ìƒìŠ¹ì´ ë‚˜íƒ€ë‚˜ë¯€ë¡œ ê¸‰ì„± ì‹¬ê·¼ê²½ìƒ‰ê³¼ì˜ ê°ë³„ì´ ì¤‘ìš”í•˜ë‹¤. êµ­ì‹œì—ì„œ ê¸‰ì„± ì‹¬ê·¼ì—¼ì€ ë³´í†µ ê°ì—¼ ê³¼ê±°ë ¥ì´ ìˆì§€ë§Œ HTN/DMê³¼ ê°™ì€ ë‚´ê³¼ì  ê³¼ê±°ë ¥ì´ ì£¼ì–´ì§€ì§€ ì•Šìœ¼ë©°, ìƒëŒ€ì ìœ¼ë¡œ ë‚®ì€ ì—°ë ¹ëŒ€(ì²­ì†Œë…„~40/50ëŒ€)ì˜ ì¦ë¡€ê°€ ì¶œì œëœë‹¤. ë°˜ëŒ€ë¡œ ê¸‰ì„± ì‹¬ê·¼ê²½ìƒ‰ì€ ì´ì „ì—ë„ ìš´ë™ ì‹œ ì¼ì‹œì  anginal painì´ ë°œìƒí–ˆë˜ ê³¼ê±°ë ¥, HTN/DM/dyslipidemiaì˜ ê³¼ê±°ë ¥, í¡ì—°ë ¥ê³¼ ë†’ì€ ì—°ë ¹ëŒ€(50ëŒ€ ì´ìƒ)ê°€ ì£¼ì–´ì§€ëŠ”

</details>

<details>
<summary>5. 1672_3928_í—ˆí˜ˆì„± ë‡Œì¡¸ì¤‘.html (5/8)</summary>

ì œëª©: í—ˆí˜ˆì„± ë‡Œì¡¸ì¤‘  4. ì§„ë‹¨   1) ì´ˆê¸° í‰ê°€   (1)  ë‡Œ CT :  ë³´í†µ 1ì°¨ ê²€ì‚¬ë¡œ ì‚¬ìš©   â‘  ì¥ì : ì‘ê¸‰ ìƒí™©ì—ì„œ ì‹ ì†í•˜ê²Œ ë‡Œì¶œí˜ˆì„ ê°ë³„   â‘¡ ë‹¨ì : ê¸‰ì„± ë‡Œê²½ìƒ‰ì˜ ìœ ë¬´ë‚˜ ë¶€ìœ„ê°€ ì˜ ê´€ì°°ë˜ì§€ ì•ŠìŒ   â‘¢ ê¸‰ì„± ë‡Œê²½ìƒ‰ ì†Œê²¬:   Loss of gray/white-matter differentiation, hyperdense artery     (2)  ë‡Œ MRI   -  í™•ì‚°ê°•ì¡°ì˜ìƒ (diffusion-weighted imaging, DWI)   â‘    ì¥ì :  ê¸‰ì„± ë‡Œê²½ìƒ‰ í‰ê°€ ê°€ëŠ¥   â‘¡ ë‹¨ì : CTë³´ë‹¤ ê¸´ ê²€ì‚¬ì‹œê°„, ì‹¬ë°•ë™ê¸° ë“±ì˜ ê¸ˆê¸°ì¦ ì¡´ì¬   â‘¢  ê¸‰ì„± ë‡Œê²½ìƒ‰ ì†Œê²¬:  ê³ ì‹ í˜¸(í•˜ì–—ê²Œ) ë¡œ ë³´ì„     (3) Perfusion scan: CT ë“±ì„ ì´ìš©í•´ ë‡Œí˜ˆë¥˜ëŸ‰ ë“±ì„ ì´ë¯¸ì§€í™”í•´ penumbraë¥¼ ì‹œê°ì ìœ¼ë¡œ í™•ì¸     2) í™•ì§„: ì¹´í…Œí„° ê¸°ë°˜ ë‡Œí˜ˆê´€ì¡°ì˜ìˆ  (catheter-based cerebral angiography)   (1) í˜ˆê´€ ë³‘ë³€ì˜ ìœ„ì¹˜, í¬ê¸°

</details>

<details>
<summary>6. 1652_3895_ë¶€ì‹ ê¸°ëŠ¥ì €í•˜ì¦.html (4/7)</summary>

ì œëª©: ë¶€ì‹ ê¸°ëŠ¥ì €í•˜ì¦  3. ì§„ë‹¨   1)  ê¸‰ì† ë¶€ì‹ ê²‰ì§ˆìê·¹í˜¸ë¥´ëª¬ ìê·¹ ê²€ì‚¬ (rapid ACTH stimulation test)   (1) í•©ì„± ACTH(cosyntropin) íˆ¬ì—¬ í›„ cortisol levelì„ í†µí•´ adrenal glandì˜ ê¸°ëŠ¥ í™•ì¸   (2) ê¸°ì¤€: íˆ¬ì—¬ 30~60ë¶„ í›„ cortisol <  16 ~ 18  Î¼g/dL   (3) í•œê³„: HPA axis disruption ì´ˆê¸°ì—ëŠ” adrenal gland atrophyê°€ ì•„ì§ ì¼ì–´ë‚˜ì§€ ì•Šì•„ ACTH stimulationì— ì •ìƒì ìœ¼ë¡œ ë°˜ì‘í•  ìˆ˜ ìˆìŒ (ë‡Œí•˜ìˆ˜ì²´ ê¸°ëŠ¥ì €í•˜ì¦ ë°œìƒ 4ì£¼ ì´ë‚´)     2) Insulin tolerance test (ITT)   (1) HPA disruption ì´ˆê¸°ì— rapid ACTH stimulation test ìƒ ì •ìƒìœ¼ë¡œ í™•ì¸ë˜ëŠ” ê²½ìš° ì‹œí–‰ ê°€ëŠ¥í•¨   (2) Rapid ACTH stimulation testì— ë¹„í•´ invasiveí•œ ê²€ì‚¬ (DM, CVDì—ì„œ ìœ„í—˜ì„±â†‘)

</details>

<details>
<summary>7. 1648_3875_ë‚´ë¶„ë¹„ ì§ˆí™˜ì˜ ì ‘ê·¼.html (3/3)</summary>

ì œëª©: ë‚´ë¶„ë¹„ ì§ˆí™˜ì˜ ì ‘ê·¼  2. í˜¸ë¥´ëª¬ì˜ ì¸¡ì •   ë‚´ë¶„ë¹„ ì§ˆí™˜ì˜ í‰ê°€ ì‹œì—ëŠ” í˜¸ë¥´ëª¬ì´ë‚˜ ëŒ€ì‚¬ ë¬¼ì§ˆì˜ ì–‘ì„ ì¸¡ì •í•˜ëŠ” ë°©ë²•ê³¼, í”¼ë“œë°± ì¡°ì ˆê¸°ì „ì´ ì •ìƒì ìœ¼ë¡œ ì´ë£¨ì–´ì§€ëŠ”ì§€ í™•ì¸í•˜ëŠ” ë°©ë²•ì„ ì´ìš©í•  ìˆ˜ ìˆë‹¤.     1) ìê·¹ê²€ì‚¬(stimulation test) :  í˜¸ë¥´ëª¬ì €í•˜ì¦ (hypofunction)ì´ ì˜ì‹¬ë  ë•Œ   â€¢ í˜¸ë¥´ëª¬ ë¶„ë¹„ë¥¼ ì´‰ì§„í•˜ëŠ” ìê·¹ì„ ì¤€ í›„ ì ì ˆí•˜ê²Œ ë¶„ë¹„ë˜ëŠ”ì§€ í™•ì¸     2) ì–µì œê²€ì‚¬(suppression test) :  í˜¸ë¥´ëª¬í•­ì§„ì¦ (hyperfunction)ì´ ì˜ì‹¬ë  ë•Œ   â€¢ í˜¸ë¥´ëª¬ ë¶„ë¹„ë¥¼ ì–µì œí•˜ëŠ” ìê·¹ì„ ì¤€ í›„ ì ì ˆí•˜ê²Œ ì–µì œë˜ëŠ”ì§€ í™•ì¸         Harrison 21e, pp.2881-2891

</details>

<details>
<summary>8. 1696_3954_ì™¸ìƒì˜ ì‘ê¸‰ì²˜ì¹˜.html (1/6)</summary>

ì œëª©: ì™¸ìƒì˜ ì‘ê¸‰ì²˜ì¹˜  ë³¸ ë‹¨ì›ì—ì„œëŠ” ì™¸ìƒ í™˜ìì˜ ì‘ê¸‰ì²˜ì¹˜ ì¤‘ ì¼ì°¨í‰ê°€(primary survey)ì— ëŒ€í•´ ë‹¤ë£¬ë‹¤. íŠ¹íˆ ì¼ì°¨í‰ê°€ì˜ A~E ì¤‘ Aì— í•´ë‹¹í•˜ëŠ” ê¸°ë„ í™•ë³´ì— ëŒ€í•´ ìƒì„¸íˆ ì¶œì œëœë‹¤. Cricothyroidotomyë¥¼ í†µí•œ surgical airway í™•ë³´ì˜ ì ì‘ì¦ì´ ë¬´ì—‡ì¸ì§€ ì˜ ì•Œì•„ë‘ì–´ì•¼ í•œë‹¤. ì‹ ì²´ì˜ ê°œë³„ ë¶€ë¶„ì˜ ì™¸ìƒì— ëŒ€í•œ ë‚´ìš©ì€ ë‹¤ìŒê³¼ ê°™ì€ ê°œë³„ íŒŒíŠ¸ì—ì„œ ë‹¤ë£¨ê³  ìˆë‹¤. ( ì™¸ìƒì„± ë‡Œì†ìƒ ,  ì²™ìˆ˜ ì™¸ìƒ ,  í‰ë¶€ ì™¸ìƒ ,  ë³µë¶€ ì™¸ìƒ ,  ê³¨ë°˜ ì™¸ìƒ ,  ë¹„ë‡¨ê¸°ê³„ ì™¸ìƒ ,  ê³¨ì ˆ ì´ë¡  )     1ì°¨ í‰ê°€ ì§„í–‰ì‹œ pulse oximetry, ABGA, í˜ˆì¤‘ lactate, CXR, ECG, FAST, ë„ë‡¨ê´€ urine output ë“± ë‹¤ì–‘í•œ ê²€ì‚¬ì˜ ë„ì›€ì„ ë°›ì„ ìˆ˜ ìˆë‹¤. ì›ì¹™ì ì¸ ìš°ì„ ë„ëŠ” Aë¶€í„° Eê¹Œì§€ ìˆœì„œëŒ€ë¡œì§€ë§Œ, ì‹¤ì œë¡œëŠ” ë¹ ë¥¸ ì²˜ì¹˜ë¥¼ ìœ„í•´ ë™ì‹œë‹¤ë°œì ìœ¼ë¡œ ì§„í–‰ëœë‹¤.

</details>

<details>
<summary>9. 1888_4435_ì •ì‹ ê³¼ì  í‰ê°€.html (6/6)</summary>

ì œëª©: ì •ì‹ ê³¼ì  í‰ê°€  5. ì‹ ê²½ì¸ì§€ê¸°ëŠ¥ê²€ì‚¬(neurocognitive function test)   1) ê°œë…   (1) ì—¬ëŸ¬  ì¸ì§€ê¸°ëŠ¥ ì˜ ê¸°ëŠ¥ ìˆ˜ì¤€ì„ ë¬¸ë‹µì‹ í˜•íƒœë¡œ ì§ˆì  í˜¹ì€ ì–‘ì  í‰ê°€   (2) ëª©ì : ì£¼ë¡œ  ì¸ì§€ê¸°ëŠ¥ ì €í•˜ê°€ ìˆëŠ” í™˜ì ì—ì„œ ì¸ì§€ê¸°ëŠ¥ ì €í•˜ì˜ ì •ë„ë¥¼ íŒŒì•…     2) ê°„ì´ì •ì‹ ìƒíƒœê²€ì‚¬(mini mental status examination, MMSE)   (1) ê°€ì¥ ë„ë¦¬ ì‚¬ìš©ë˜ëŠ” ì„ ë³„ê²€ì‚¬   (2) ì§€ë‚¨ë ¥, ì£¼ì˜ë ¥ ë° ê³„ì‚°, ì–¸ì–´ëŠ¥ë ¥, ì§‘ì¤‘ë ¥, ê³µê°„êµ¬ì„± ëŠ¥ë ¥ ë“±ì„ ì‹ ì†í•˜ê²Œ í‰ê°€       ì‹œê°„ ì§€ë‚¨ë ¥ (5)   â€¢ í˜„ì¬ ì—°ë„ / ì›” / ì¼ / ìš”ì¼ / ê³„ì ˆ       ì¥ì†Œ ì§€ë‚¨ë ¥ (5)   â€¢ í˜„ì¬ ë‚˜ë¼ / ì‹œÂ·ë„ / ì¥ì†Œ ì´ë¦„ / ì¥ì†Œ ëª©ì  / ì¸µ ìˆ˜       ê¸°ì–µ ë“±ë¡ (3)   â€¢ ë¹„í–‰ê¸°, ì—°í•„, ì†Œë‚˜ë¬´ (ë¶ˆëŸ¬ì£¼ê³  ì¦‰ì‹œ ì¬í™•ì¸)       ì£¼ì˜ ì§‘ì¤‘ë ¥ (5)   â€¢ Serial 7 test (100 - 7 - 7 - 7 - 7 -7)       ê¸°ì–µ íšŒìƒ

</details>

<details>
<summary>10. 1800_4195_ì‹¬ë¶€ì „ ì›ì¸, ì¦ìƒ, ì§„ë‹¨.html (6/6)</summary>

ì œëª©: ì‹¬ë¶€ì „ ì›ì¸, ì¦ìƒ, ì§„ë‹¨  5. ì§„ë‹¨   1) ì§„ë‹¨ì  ì ‘ê·¼ì˜ ìˆœì„œ: Hx/PEx â†’ CXR / ECG â†’  BNP  â†’  ì‹¬ì´ˆìŒíŒŒ   ìˆœìœ¼ë¡œ ì§„í–‰   * ì¦‰, CXR í˜¹ì€ ECG ì†Œê²¬ì´ ì£¼ì–´ì§€ê³  ë‹¤ìŒ ê²€ì‚¬ë¡œ BNP ë˜ëŠ” echocardiographyë¥¼ ë‹µìœ¼ë¡œ ê³ ë¥´ëŠ” ë¬¸ì œê°€ ë§ì´ ì¶œì œëœë‹¤.     2) CXR:   Cardiomegaly ,  pulmonary congestion , pleural effusion     3) ECG:  HFë¥¼ ì§„ë‹¨í•˜ê¸°ë³´ë‹¤ëŠ” HFì˜ ì›ì¸ì§ˆí™˜ ì¶”ì •ì— ë„ì›€ì´ ë¨   (1) Pathologic Q wave, ST elevation: ê´€ìƒë™ë§¥ì§ˆí™˜   (2) Low QRS: RCMP ë“±   (3) Irregularly irregular RR interval: AF     4)  ë‡Œë‚˜íŠ¸ë¥¨ì´ë‡¨í©í‹°ë“œ (brain natriuretic peptide, BNP)   (1) ë¶„ë¹„: ì‹¬ì‹¤ ìš©ì  ì¦ê°€ ë° ì••ë ¥ ê³¼ë¶€í•˜ì— ë°˜ì‘í•˜ì—¬ ì‹¬ê·¼ì„¸í¬ì—ì„œ ë¶„ë¹„   (2) ê¸°ëŠ¥: í‰í™œ

</details>

### ğŸ’¬ Answer
The provided text snippets offer a comprehensive view of diagnostic and evaluation methods used in various medical conditions. To answer the question about the initial assessment items for a patient hospitalized with heart failure, let's synthesize information from the relevant snippets:

**Relevant Snippets & Analysis:**

*   **Snippet 10 (ì‹¬ë¶€ì „ ì›ì¸, ì¦ìƒ, ì§„ë‹¨):** This snippet directly addresses the diagnostic approach to heart failure. It outlines the sequence: History/Physical Exam (Hx/PEx) â†’ Chest X-ray (CXR) / Electrocardiogram (ECG) â†’ Brain Natriuretic Peptide (BNP) â†’ Echocardiography. This snippet explicitly states the order of diagnostic tests for heart failure.

*   **Snippet 8 (ì™¸ìƒì˜ ì‘ê¸‰ì²˜ì¹˜):** This snippet, while focused on trauma, mentions several tests that can be helpful in the initial assessment of any patient, including pulse oximetry, ABGA, í˜ˆì¤‘ lactate, CXR, ECG, and ë„ë‡¨ê´€ urine output.

*   **Snippet 3 (ì‹¬í™” 1. ì‹¬ì´ˆìŒíŒŒ : Echocardiography):** This snippet highlights the importance of echocardiography in evaluating heart conditions.

*   **Snippet 4 (ì‹¬ê·¼ì—¼ 3. ê²€ì‚¬ì†Œê²¬):** discusses CXR, ECG, í˜ˆì•¡ê²€ì‚¬(BNP, ì‹¬ê·¼ íš¨ì†Œ ìƒìŠ¹) for myocarditis.

**Comprehensive Answer:**

Based on the snippets, the initial evaluation items for a patient hospitalized with heart failure are:

1.  **History and Physical Examination (Hx/PEx):** This involves gathering information about the patient's symptoms, past medical history, medications, and conducting a thorough physical examination to assess vital signs, heart and lung sounds, and signs of fluid overload (e.g., edema).

2.  **Chest X-ray (CXR):** To evaluate for cardiomegaly (enlarged heart), pulmonary congestion (fluid in the lungs), and pleural effusion (fluid around the lungs) - all common findings in heart failure.

3.  **Electrocardiogram (ECG):** To assess the heart's electrical activity and identify potential underlying causes of heart failure, such as ischemic heart disease (pathologic Q waves, ST elevation), restrictive cardiomyopathy (low QRS voltage), or atrial fibrillation (irregularly irregular RR intervals).

4.  **Brain Natriuretic Peptide (BNP):** A blood test to measure the levels of BNP, a hormone released by the heart in response to increased volume and pressure overload. Elevated BNP levels support the diagnosis of heart failure.

5.  **Pulse Oximetry:** To assess the patient's oxygen saturation level.

**Additional Considerations:**

*   **Echocardiography:** While Snippet 10 places echocardiography after CXR/ECG and BNP, it is a crucial component of the diagnostic process. It provides detailed information about the heart's structure and function, including ejection fraction, valve abnormalities, and wall motion abnormalities. It may not be part of the *very initial* assessment, but it is typically performed soon after.

*   **Blood work:** In addition to BNP, other blood tests may be performed to evaluate kidney function, electrolytes, and complete blood count.

*   **Arterial Blood Gas (ABG):** May be performed to assess the patient's oxygenation and acid-base balance.

*   **Urine output:** Monitoring urine output via catheterization can help assess kidney function and response to treatment.

**In summary, the initial evaluation of a heart failure patient focuses on rapid assessment of the patient's clinical status, identifying potential causes and triggers, and initiating appropriate treatment.** The specific order and inclusion of tests may vary depending on the patient's presentation and the clinical context.

---

## ğŸ” Query
ì‹¬ë¶€ì „ìœ¼ë¡œ ì…ì›í•œ í™˜ìì—ê²Œ ì²˜ìŒ ì‹œí–‰í•´ì•¼ í•  ì²˜ì¹˜ëŠ”?

### ğŸ“š Context

<details>
<summary>1. 1696_3953_ì‹¬ì •ì§€ í›„ í•©ë³‘ì¦.html (3/4)</summary>

ì œëª©: ì‹¬ì •ì§€ í›„ í•©ë³‘ì¦  2. ROSC í™˜ìì˜ ì²˜ì¹˜   ì•„ë˜ ìˆœì„œëŒ€ë¡œ ì§„í–‰í•œë‹¤.     1) ê¸°ê´€ ì‚½ê´€: Â ì†Œìƒìˆ  ê³¼ì •ì—ì„œ í™•ë³´ë˜ì§€ ì•Šì•˜ë‹¤ë©´ ì¦‰ì‹œ ì‹œí–‰     2) ì‚°ì†Œ íˆ¬ì—¬: ìš°ì„  100% ë¡œ ê³µê¸‰í•œ í›„ ë‹¤ìŒ ëª©í‘œì¹˜ì— ë§ê²Œ ë†ë„ë¥¼ ë‚®ì¶¤   (1) í˜¸í¡ìˆ˜ 10íšŒ/ë¶„   (2) SpO 2 Â 92~98%   (3) PaCO 2 Â 35~45 mmHg     3) ì €í˜ˆì•• ë°©ì§€   (1) ëª©í‘œì¹˜: SBP > 90 mmHg, MAP > 65 mmHg   (2) ëª©í‘œì¹˜ë¥¼ ë§ì¶”ê¸° ìœ„í•´ IV crystalloid, vasopressor, inotrope ì‚¬ìš©     4) 12-lead ECG:  STEMI, ë¶ˆì•ˆì •í•œ cardiogenic shock ë“±ì´ ìˆìœ¼ë©´ primary PCI ì‹œí–‰     5)  ëª…ë ¹ì— ë”°ë¥´ëŠ”ì§€ (obeying command) í™•ì¸   (1)  ë”°ë¥´ì§€ ëª»í•˜ë©´ ëª©í‘œì²´ì˜¨ìœ ì§€ì¹˜ë£Œ ì‹œí–‰   (2) ë”°ë¥¸ë‹¤ë©´ ê¸°íƒ€ ì²˜ì¹˜ ì‹œí–‰

</details>

<details>
<summary>2. 1864_4329_ìˆ˜ìˆ  ì „ ì²˜ì¹˜.html (1/5)</summary>

ì œëª©: ìˆ˜ìˆ  ì „ ì²˜ì¹˜  ìˆ˜ìˆ ì€ í™˜ì ê°œì¸ì˜ ì‚¶ì— ìˆì–´ì„œ ë§¤ìš° í° ì‚¬ê±´ì´ë©°, ì‹ ì²´ì ìœ¼ë¡œë„ ë§ì€ ë³€í™”ë¥¼ ë™ë°˜í•˜ë©°, ì´ ì¤‘ ì¶œí˜ˆ ë“± ëª‡ëª‡ì€ ì‹¬ê°í•œ í•©ë³‘ì¦ìœ¼ë¡œ í™˜ìì˜ ì˜ˆí›„ì— í° ì˜í–¥ì„ ë¼ì¹  ìˆ˜ ìˆë‹¤. ë³¸ ë‹¨ì›ì—ì„œëŠ” í™˜ìì˜ ê¸°ì €ì§ˆí™˜ì´ë‚˜ ì•½ë¬¼ë ¥ì— ë”°ë¼ ìˆ˜ìˆ  ì „ ì‹œí–‰í•´ì•¼ í•˜ëŠ” ì¡°ì¹˜ë“¤ì— ëŒ€í•´ ë‹¤ë£¬ë‹¤. íŠ¹íˆ í•­í˜ˆì „ ì•½ë¬¼ì„ ì œì œë³„ë¡œ ì–¸ì œ ëŠì–´ì•¼ í•˜ëŠ”ì§€, ìˆ˜ìˆ  ì „ ì¶œí˜ˆ ë° í˜ˆì „ ê°€ëŠ¥ì„±ì— ëŒ€í•œ ê²€ì‚¬ í•´ì„ê³¼ ì¡°ì¹˜ê°€ ë§ì´ ì¶œì œëœë‹¤.

</details>

<details>
<summary>3. 2440_4450_ì§€ì—­ì‚¬íšŒì •ì‹ ì˜í•™.html (2/2)</summary>

ì œëª©: ì§€ì—­ì‚¬íšŒì •ì‹ ì˜í•™  1. ì…ì›ë°©ë²•   ì •ì‹ ê±´ê°•ì¦ì§„ ë° ì •ì‹ ì§ˆí™˜ì ë³µì§€ì„œë¹„ìŠ¤ ì§€ì›ì— ê´€í•œ ë²•ë¥        ì…ì› ì¢…ë¥˜   ë™ì˜ì˜ ì£¼ì²´   ë¹„ê³          ìì˜ì…ì›   (ì œ41ì¡°)     í™˜ì ë³¸ì¸   í™˜ì ë³¸ì¸ì´ ì›í•˜ì—¬ ì…ì›         ë™ì˜ì…ì›   (ì œ42ì¡°)     ë³´í˜¸ìì˜ë¬´ì   í™˜ìëŠ” ì…ì›ì˜ í•„ìš”ì„±ì„ ëŠë‚Œ         ë³´í˜¸ì˜ë¬´ìì— ì˜í•œ ì…ì›   (ì œ43ì¡°)       ë³´í˜¸ìì˜ë¬´ì 2ëª… ì´ìƒ &   ì •ì‹ ê³¼ ì „ë¬¸ì˜     í™˜ìëŠ” ë¹„ìì˜ì ìœ¼ë¡œ ì…ì›         ìì¹˜ë‹¨ì²´ì¥ì— ì˜í•œ ì…ì›   (ì œ44ì¡°)     ìì¹˜ë‹¨ì²´ì¥ì˜ & ì •ì‹ ê³¼ ì „ë¬¸ì˜           ì‘ê¸‰ì…ì›   (ì œ50ì¡°)     ì˜ì‚¬ & ê²½ì°°ê´€   ì •ì‹ ì§ˆí™˜ì ë¡œ  ìí•´ ë° íƒ€í•´ì˜ ìœ„í—˜ ì´ í´ ë•Œ (ì œ41ì¡°~ì œ44ì¡°ë¥¼ ì ìš©í•  ì‹œê°„ì  ì—¬ìœ ê°€ ì—†ìŒ)             Kaplan & Sadock 12e, Ch.30

</details>

<details>
<summary>4. 1759_4083_ì¤‘ì¶” ì‹ ê²½ê³„ì˜ ê°ì—¼ ì§ˆí™˜.html (5/7)</summary>

ì œëª©: ì¤‘ì¶” ì‹ ê²½ê³„ì˜ ê°ì—¼ ì§ˆí™˜  4. ì§„ë‹¨   1) ì„¸ê·  ì˜ì‹¬ ì‹œ   (1)  ë‡Œì²™ìˆ˜ì•¡ì˜ ê·¸ëŒ ì—¼ìƒ‰ ë° ë°°ì–‘ ì—ì„œ ì›ì¸ê·  ë™ì •í•˜ì—¬ í™•ì§„   (2) ì¶”ê°€ë¡œ, ìˆ˜ë§‰ì—¼ì´ ì˜ì‹¬ë˜ëŠ” ëª¨ë“  í™˜ìì—ì„œ í˜ˆì•¡ ë°°ì–‘ ê²€ì‚¬(80-90%ì—ì„œ ì›ì¸ê·  ë™ì •ë¨)   3) ë°”ì´ëŸ¬ìŠ¤ ì˜ì‹¬ ì‹œ   (1) ë‡Œì²™ìˆ˜ì•¡ ë°°ì–‘ ê²€ì‚¬ ë° PCRë¡œ í™•ì§„   (2) CT/MRI: íŠ¹íˆ ì¸¡ë‘ì—½ ê´€ë ¨ ì†Œê²¬ì´ í™•ì¸ë˜ë©´ HSVì˜ ê°€ëŠ¥ì„±  â†‘

</details>

<details>
<summary>5. 1804_4172_ê°ì—¼ ì‹¬ë‚´ë§‰ì—¼.html (6/6)</summary>

ì œëª©: ê°ì—¼ ì‹¬ë‚´ë§‰ì—¼  5. ì¹˜ê³¼ ì¹˜ë£Œ ì‹œ ì˜ˆë°©   1) ê°œë…: ì¹˜ê³¼ ì¹˜ë£Œ ì‹œ êµ¬ê°• ì ë§‰ ì†ìƒ â†’  íŠ¹ì • í™˜ìêµ°ì˜ ê²½ìš° IE ë°œìƒ ìœ„í—˜ì´ ë†’ì•„ ì˜ˆë°©ì  í•­ìƒì œ í•„ìš”   (1) ë°œì¹˜   (2) ì‡ëª¸/ì¹˜ì•„ë¿Œë¦¬ë¥¼ ê±´ë“œë¦¬ëŠ” ì‹œìˆ    (3) ê¸°íƒ€ ìˆ˜ìˆ : ì„í”Œë€íŠ¸, ì¹˜ì£¼ìˆ˜ìˆ , êµ¬ê°• ë‚´ ìƒê²€ ë“±     2) ì˜ˆë°©ì  í•­ìƒì œ:  ì¹˜ê³¼ ì¹˜ë£Œ ì‹œì‘  30~60ë¶„ ì „   â€¢  Amoxicillin  2g PO, ampicillin 2g IM/IV, cefazolin 1g IM/IV, ceftriaxone 1g IM/IV     3) ì ì‘ì¦   (1) ì´ì „ IE ë³‘ë ¥   (2)   ì¸ê³µ íŒë§‰ ,  íŒë§‰ ê´€ë ¨ ê¸°íƒ€ ì¸ê³µ ì‚½ì…ë¬¼, ì‹¬ì‹¤ë³´ì¡°ì¥ì¹˜   (3) ì„ ì²œì„± ì‹¬ì§ˆí™˜: ì•„ë˜ì™€ ê°™ì„ ê²½ìš°ì—ë§Œ ì‹œí–‰   â‘  êµì •ë˜ì§€ ì•Šì€ ì„ ì²œì„± ì²­ìƒ‰ì¦ ì‹¬ì§ˆí™˜   â‘¡   íŒë§‰ì„± ì¸ê³µì‚½ì…ë¬¼ or ì¸ê³µì ì¸ systemic-pulmonary shuntë¥¼ ì´ìš©í•´ êµì •í•œ ì„ ì²œì„± ì‹¬ì§ˆí™˜   â‘¢ ì„ ì²œì„± ì‹¬ì§ˆí™˜ êµì • í›„ 6ê°œì›” ì´ë‚´ or resid

</details>

<details>
<summary>6. 1882_4401_í—Œí˜ˆì ê´€ë¦¬.html (1/2)</summary>

ì œëª©: í—Œí˜ˆì ê´€ë¦¬  í—Œí˜ˆì ì‹ ì›í™•ì¸ ë° ê±´ê°•ì§„ë‹¨   í˜ˆì•¡ê´€ë¦¬ë²• ì œ7ì¡°(í—Œí˜ˆìì˜ ì‹ ì› í™•ì¸ ë° ê±´ê°•ì§„ë‹¨ ë“±)   â‘  í˜ˆì•¡ì›ì€ ë³´ê±´ë³µì§€ë¶€ë ¹ìœ¼ë¡œ ì •í•˜ëŠ” ë°”ì— ë”°ë¼ Â  ì±„í˜ˆ ì „ì— í—Œí˜ˆìì— ëŒ€í•˜ì—¬ ì‹ ì› í™•ì¸ ë° ê±´ê°•ì§„ë‹¨ì„ í•˜ì—¬ì•¼ í•œë‹¤.     í˜ˆì•¡ê´€ë¦¬ë²• ì‹œí–‰ê·œì¹™ ì œ6ì¡°(í—Œí˜ˆìì˜ ê±´ê°•ì§„ë‹¨ ë“±) ì œ1í•­, ì œ2í•­     â‘  ë²• ì œ7ì¡°ì œ1í•­ì— ë”°ë¼ í˜ˆì•¡ì›ì€ í—Œí˜ˆìë¡œë¶€í„° ì±„í˜ˆí•˜ê¸° ì „ì— ì‚¬ì§„ì´ ë¶™ì–´ ìˆì–´ ë³¸ì¸ì„ì„ í™•ì¸í•  ìˆ˜ ìˆëŠ” ì£¼ë¯¼ë“±ë¡ì¦, ì—¬ê¶Œ, í•™ìƒì¦, ê·¸ ë°–ì˜ ì‹ ë¶„ì¦ëª…ì„œì— ë”°ë¼ ê·¸  ì‹ ì›ì„ í™•ì¸ í•˜ì—¬ì•¼ í•œë‹¤. ë‹¤ë§Œ, í•™ìƒ, êµ°ì¸ ë“±ì˜ ë‹¨ì²´í—Œí˜ˆì˜ ê²½ìš° ê·¸ ê´€ë¦¬ã†ê°ë…ìì˜ í™•ì¸ìœ¼ë¡œ ê°ˆìŒí•  ìˆ˜ ìˆë‹¤.    â‘¡ ì œ1í•­ì— ë”°ë¥¸ ì‹ ì›í™•ì¸ í›„ì— í˜ˆì•¡ì›ì€ í—Œí˜ˆìì— ëŒ€í•˜ì—¬ ì±„í˜ˆì„ ì‹¤ì‹œí•˜ê¸° ì „ì— ë‹¤ìŒ ê° í˜¸ì— í•´ë‹¹í•˜ëŠ”  ê±´ê°•ì§„ë‹¨ ì„ ì‹¤ì‹œí•˜ì—¬ì•¼ í•œë‹¤.   1. ê³¼ê±°ì˜ í—Œí˜ˆê²½ë ¥ ë° í˜ˆì•¡ê²€ì‚¬ê²°ê³¼ì™€ ì±„í˜ˆê¸ˆì§€ëŒ€ìƒì ì—¬ë¶€ì˜ ì¡°íšŒ   2. ë¬¸ì§„ã†ì‹œì§„ ë° ì´‰ì§„   3. ì²´ì˜¨ ë° ë§¥ë°• ì¸¡ì •   4. ì²´ì¤‘ ì¸¡ì •   5. í˜ˆì•• ì¸¡ì •

</details>

<details>
<summary>7. 1647_3854_ì„±ì¸ì˜ ì˜ˆë°©ì ‘ì¢….html (4/7)</summary>

ì œëª©: ì„±ì¸ì˜ ì˜ˆë°©ì ‘ì¢…  3. ìœ„í—˜êµ°ì— ë”°ë¥¸ ì˜ˆë°©ì ‘ì¢…   1)  ì•„ë¬´ ìœ„í—˜ìš”ì¸ì´ ì—†ëŠ” ì„±ì¸ì˜ ì˜ˆë°©ì ‘ì¢… ìŠ¤ì¼€ì¤„   (1) íŒŒìƒí’-ë””í”„í…Œë¦¬ì•„-ë°±ì¼í•´:  ë§¤ 10ë…„   (2) Aí˜•ê°„ì—¼:  20~39ì„¸   (3) ì¸í”Œë£¨ì—”ì:  50ì„¸ë¶€í„° ë§¤ 1ë…„   (4) ëŒ€ìƒí¬ì§„:  60ì„¸   (5) íë ´êµ¬ê·  : 65ì„¸     2)  ë¬´ë¹„ì¦ (asplenia):  ë¹„ì¥ì ˆì œìˆ  (splenectomy)ì„ ë°›ì€ í™˜ì,  ì„ ì²œì  ë¬´ë¹„ì¦ ë“±   (1)  íë ´êµ¬ê·    (2)  ìˆ˜ë§‰êµ¬ê·    (3) bí˜• í—¤ëª¨í•„ë£¨ìŠ¤ ì¸í”Œë£¨ì—”ì   * ìœ„ 3ê°œì˜ ë°±ì‹ ì— í•´ë‹¹í•˜ëŠ” ê· , ì¦‰ S. pneumoniae, N. meningitidis, H. influenzae type bëŠ” í”¼ë§‰ì„¸ê· (capsulated bacteria)ì— í•´ë‹¹í•˜ë©° ë¬´ë¹„ì¦ í™˜ìëŠ” ì´ì— íŠ¹íˆ ì·¨ì•½í•˜ê¸° ë•Œë¬¸ì— ë°˜ë“œì‹œ ì˜ˆë°©ì ‘ì¢…ì„ ë°›ì•„ì•¼ í•œë‹¤.     3) ê¸°íƒ€ ê³ ìœ„í—˜êµ°     ë°±ì‹  ì ‘ì¢… ê¶Œê³    ìƒë°±ì‹  (ìˆ˜ë‘, ëŒ€ìƒí¬ì§„, MMR) ê¸ˆê¸°     ê³ ìœ„í—˜êµ°   ì¸í”Œë£¨ì—”ì

</details>

<details>
<summary>8. 1647_3854_ì„±ì¸ì˜ ì˜ˆë°©ì ‘ì¢….html (1/7)</summary>

ì œëª©: ì„±ì¸ì˜ ì˜ˆë°©ì ‘ì¢…  êµ­ì‹œì™€ ì„ì¢…í‰ì— ë¹ ì§€ì§€ ì•Šê³  ë°˜ë“œì‹œ ì¶œì œë˜ëŠ” ë¶€ë¶„ì´ë‹¤. í™˜ìì— ìƒí™©ì— ë§ê²Œ í•„ìš”í•œ ì˜ˆë°©ì ‘ì¢…ì„ ë¬»ëŠ” ë¬¸ì œì˜ í˜•íƒœë¡œ í•­ìƒ ì¶œì œëœë‹¤. ì¼ë°˜ ì„±ì¸ì˜ ì˜ˆë°©ì ‘ì¢…ì—ì„œ ì¸í”Œë£¨ì—”ì, Tdap/Td, íë ´êµ¬ê· (23ê°€, 13ê°€)ë¥¼ íŠ¹íˆ ì˜ ì •ë¦¬í•´ë‘ê³ , í•´ì™¸ì—¬í–‰ ì‹œ ë°©ë¬¸í•˜ëŠ” ì§€ì—­ë³„ë¡œ í•„ìš”í•œ ì˜ˆë°©ì ‘ì¢…ë„ ì•Œì•„ë‘ì. ì˜ë£Œì§ ì‹œì‘ ì „ì— í•„ìš”í•œ ì˜ˆë°©ì ‘ì¢… ë¬¸ì œë„ ìµœê·¼ ì¶œì œë˜ì—ˆë‹¤.

</details>

<details>
<summary>9. 1636_4736_íŒ¨í˜ˆì¦.html (2/5)</summary>

ì œëª©: íŒ¨í˜ˆì¦  1. ê°ì—¼ì§ˆí™˜ì˜ ì ‘ê·¼   1) ë°œì—´   (1) ê³ ë ¹, ë©´ì—­ì €í•˜ìëŠ” ë°œì—´ì´ ë‚˜íƒ€ë‚˜ì§€ ì•Šê¸°ë„ í•¨   (2)  ì €ì²´ì˜¨ : ê°ì—¼ì´ ì‹¬í•  ê²½ìš° ë°œìƒ ê°€ëŠ¥   (3) ì¦ìƒì˜ ê¸°ë³¸ ì •ë³´: Onset, duration, ì•…í™”ì˜ ì—¬ë¶€ ë° ìœ ë°œìš”ì¸ ë“±     2) ê²€ì²´ ì±„ì·¨ ë° ê²½í—˜ì  í•­ìƒì œ   (1)  ë°°ì–‘ì„ ìœ„í•œ ê²€ì²´ ì±„ì·¨ í›„ í•­ìƒì œ íˆ¬ì—¬ê°€ ì›ì¹™   â‘  í˜ˆì•¡ë°°ì–‘: ì¼ë°˜ì ìœ¼ë¡œ 2ìŒ, ì‹¬ë‚´ë§‰ì—¼ì˜ ê²½ìš° 3ìŒ   â‘¡ ê°ë‹´ë°°ì–‘: íë ´ ë“± í˜¸í¡ê¸° ì§ˆí™˜ì˜ ê²½ìš°   â‘¢ ì†Œë³€ë°°ì–‘: ì‹ ìš°ì‹ ì—¼ ë“± ì‹ ì¥ë¹„ë‡¨ê¸° ì§ˆí™˜ì˜ ê²½ìš°   â‘£ ì¹´í…Œí„° íŒ ë°°ì–‘: ì¤‘ì‹¬ì •ë§¥ê´€ ë“±  ë„ê´€ ê°ì—¼ ì´ ì˜ì‹¬ë  ê²½ìš°   (2) ë‡Œìˆ˜ë§‰ì—¼ ì˜ì‹¬ ì‹œ ì²™ìˆ˜ì²œì â†’ CSF ê²€ì²´ ì±„ì·¨ â†’ í•­ìƒì œ íˆ¬ì—¬   â‘  í•­ìƒì œ íˆ¬ì—¬ ì „ì— ì‹¤ì‹œ   â‘¡ ë‹¨, ì•„ë˜ì˜ ê²½ìš° í˜ˆì•¡ê²€ì²´ ì±„ì·¨ë§Œ ì™„ë£Œí•˜ê³  ë°”ë¡œ í•­ìƒì œ íˆ¬ì—¬   â€¢  IICPê°€ ì˜ì‹¬ë˜ì–´ ì²™ìˆ˜ì²œì ì „ ì˜ìƒê²€ì‚¬ë¥¼ ë¨¼ì € ì§„í–‰í•´ì•¼ í•  ë•Œ   â€¢  ì²™ìˆ˜ì²œìì˜ ì²« ì‹œë„ê°€ ì‹¤íŒ¨í–ˆì„ ë•Œ   * ì›ë˜ ê²€ì²´ ì±„ì·¨ í›„ í•­

</details>

<details>
<summary>10. 1711_4015_ì„±í­í–‰.html (2/5)</summary>

ì œëª©: ì„±í­í–‰  1. ê°œìš”   1) ì§„ì°° ì „ë°˜ì— ëŒ€í•œ ì£¼ì˜ì‚¬í•­   (1) ê°ê´€ì , ë¬´ë¹„íŒì  íƒœë„   (2) ìµœì†Œ 1ì¸ì˜ ì…íšŒì¸ ë™ë°˜ (ì˜ë£Œì§„ ë‘˜ ì¤‘ í•œ ëª…ì€ í”¼í•´ìì™€ ê°™ì€ ì„±ë³„)   (3) ê³¼ì • ì „ì²´ë¥¼ í”¼í•´ìì—ê²Œ ì„¤ëª…í•˜ë©° ì§„í–‰     2) ì„±í­ë ¥ ì‘ê¸‰í‚¤íŠ¸: ì—¬ì„±ê°€ì¡±ë¶€ì—ì„œ ì œì‘í•˜ì—¬ ë³‘ì›ì— ë°°í¬í•˜ëŠ” ì •í˜•í™”ëœ ì¦ê±°ìˆ˜ì§‘ í‚¤íŠ¸   (1)  ë™ì˜ì„œ :   ê°€ì¥ ë¨¼ì € í™•ë³´ í›„ ì§„ì°° ì‹œì‘   (2) ì§„ë£Œê¸°ë¡ ì‘ì„±   (3) ì˜ë¥˜ ìˆ˜ê±°   (4) ë¶€ìŠ¤ëŸ¬ê¸°, ê°€í•´ì ì²´ì•¡/ìŒëª¨ ì±„ì·¨:  ìš°ë“œë“± (Wood's lamp)ìœ¼ë¡œ ê°€í•´ì  ì •ì•¡  í™•ì¸ ê°€ëŠ¥ (ì²­ë¡ìƒ‰ or ì£¼í™©ìƒ‰ í˜•ê´‘)     (5) ì§ˆ/ìê¶ê²½ë¶€, í•­ë¬¸/ì§ì¥, êµ¬ê°• ë©´ë´‰ ë„ë§: ì •ì ìœ ë¬´ í™•ì¸, ì„±ë§¤ê°œê°ì—¼ì— ëŒ€í•œ ì§„ë‹¨ê²€ì‚¬(PCR, ë°°ì–‘ ë“±)   (6) í”¼í•´ì í˜ˆì•¡/ì†Œë³€     3) ì˜í•™ì  ê¸°ë³¸ ê²€ì‚¬   (1) ì„ì‹  ê²€ì‚¬:  ì†Œë³€ ì„ì‹ ë°˜ì‘ê²€ì‚¬, í˜ˆì¤‘ Î²-hCG ë“±   (2) ì„±ë§¤ê°œê°ì—¼ PCR or ë°°ì–‘   â‘  ì„ì§ˆê·  (Neisseria gonorr

</details>

### ğŸ’¬ Answer
The provided texts cover a wide range of medical topics. Based on the context, the most relevant categories to analyze the question "ì‹¬ë¶€ì „ìœ¼ë¡œ ì…ì›í•œ í™˜ìì—ê²Œ ì²˜ìŒ ì‹œí–‰í•´ì•¼ í•  ì²˜ì¹˜ëŠ”? (What is the first treatment to be performed on a patient admitted with heart failure?)" are:

**1. Post-Cardiac Arrest Care (ì‹¬ì •ì§€ í›„ í•©ë³‘ì¦, ROSC í™˜ìì˜ ì²˜ì¹˜):** While not directly about heart failure, this section discusses immediate post-resuscitation care which may be relevant if the heart failure patient experienced cardiac arrest.  The priorities are:

*   **Airway Management:** Securing the airway via intubation if not already done.
*   **Oxygenation:**  Providing 100% oxygen initially and then titrating to a target SpO2 of 92-98% and PaCO2 of 35-45 mmHg.
*   **Blood Pressure Management:** Preventing hypotension with a target SBP > 90 mmHg or MAP > 65 mmHg, using IV crystalloids, vasopressors, or inotropes as needed.
*   **ECG:** Obtaining a 12-lead ECG to identify STEMI or cardiogenic shock, potentially leading to primary PCI.
*   **Neurological Assessment:** Assessing the patient's responsiveness (obeying commands) and initiating targeted temperature management if unresponsive.

**2. Pre-operative Management (ìˆ˜ìˆ  ì „ ì²˜ì¹˜):** This section highlights the importance of addressing underlying conditions and medication history before surgery, particularly focusing on antiplatelet medications and bleeding/thrombotic risks. While not directly applicable to initial heart failure management, it emphasizes the need for a thorough patient assessment.

**3. Infection-Related Sections (ì¤‘ì¶” ì‹ ê²½ê³„ì˜ ê°ì—¼ ì§ˆí™˜, ê°ì—¼ ì‹¬ë‚´ë§‰ì—¼, íŒ¨í˜ˆì¦):** These sections emphasize the importance of identifying and treating infections, which can exacerbate heart failure. Specifically:

*   **Central Nervous System Infections:**  Discusses diagnosis via CSF analysis and PCR, with consideration for CT/MRI.
*   **Infective Endocarditis (IE):**  Highlights the need for prophylactic antibiotics in specific patient groups undergoing dental procedures to prevent IE, which can significantly worsen heart failure.
*   **Sepsis:**  Emphasizes prompt blood cultures and initiation of empiric antibiotics in suspected infections.

**4. Adult Vaccination (ì„±ì¸ì˜ ì˜ˆë°©ì ‘ì¢…):**  This section underscores the importance of vaccinations, especially influenza and pneumococcal vaccines, for high-risk individuals, including those with chronic conditions like heart failure.

**Synthesis and Answer:**

Based on these categories, the initial management of a patient admitted with heart failure should prioritize the following:

1.  **Assessment:** A rapid assessment of the patient's condition is crucial. This includes:
    *   **ABCs (Airway, Breathing, Circulation):** Ensuring a patent airway, adequate oxygenation (SpO2 monitoring), and hemodynamic stability (blood pressure, heart rate).
    *   **History and Physical Exam:** Obtain a focused history, including medication list, allergies, and known cardiac history. Perform a physical exam to assess for signs of heart failure (e.g., edema, jugular venous distension, pulmonary rales).
2.  **Oxygenation:** Provide supplemental oxygen to maintain adequate oxygen saturation (typically >90%).
3.  **Monitoring:** Continuous ECG monitoring, blood pressure monitoring, and pulse oximetry are essential.
4.  **IV Access:** Establish intravenous access for medication administration and fluid management.
5.  **Diagnostic Studies:**
    *   **ECG:** Obtain a 12-lead ECG to assess for arrhythmias or ischemic changes.
    *   **Chest X-ray:** Evaluate for pulmonary edema and other lung abnormalities.
    *   **Blood Tests:** Order blood tests, including electrolytes, BUN/creatinine, cardiac enzymes (troponin), complete blood count (CBC), and BNP (B-type natriuretic peptide).
6.  **Medication:**
    *   **Diuretics:** Administer diuretics (e.g., furosemide) to reduce fluid overload.  The specific dose depends on the patient's renal function and prior diuretic use.
    *   **Vasodilators:** Consider vasodilators (e.g., nitroglycerin) if the patient has hypertension or ongoing ischemia.

**Important Considerations:**

*   The specific interventions will depend on the patient's presentation and underlying cause of heart failure.
*   It's critical to rule out acute coronary syndrome (ACS) as a potential trigger for the heart failure.
*   Address any underlying infections promptly.
*   Consider the patient's vaccination status and provide appropriate vaccinations if needed.
*   After initial stabilization, a comprehensive evaluation to determine the etiology of the heart failure and guide long-term management is essential.

---

## ğŸ” Query
ê¸‰ì„± ì‹¬ë¶€ì „ìœ¼ë¡œ ì…ì›í•œ í™˜ìì—ê²Œ ì²˜ìŒ ì‹œí–‰í•´ì•¼ í•  ì²˜ì¹˜ëŠ”?

### ğŸ“š Context

<details>
<summary>1. 1696_3953_ì‹¬ì •ì§€ í›„ í•©ë³‘ì¦.html (3/4)</summary>

ì œëª©: ì‹¬ì •ì§€ í›„ í•©ë³‘ì¦  2. ROSC í™˜ìì˜ ì²˜ì¹˜   ì•„ë˜ ìˆœì„œëŒ€ë¡œ ì§„í–‰í•œë‹¤.     1) ê¸°ê´€ ì‚½ê´€: Â ì†Œìƒìˆ  ê³¼ì •ì—ì„œ í™•ë³´ë˜ì§€ ì•Šì•˜ë‹¤ë©´ ì¦‰ì‹œ ì‹œí–‰     2) ì‚°ì†Œ íˆ¬ì—¬: ìš°ì„  100% ë¡œ ê³µê¸‰í•œ í›„ ë‹¤ìŒ ëª©í‘œì¹˜ì— ë§ê²Œ ë†ë„ë¥¼ ë‚®ì¶¤   (1) í˜¸í¡ìˆ˜ 10íšŒ/ë¶„   (2) SpO 2 Â 92~98%   (3) PaCO 2 Â 35~45 mmHg     3) ì €í˜ˆì•• ë°©ì§€   (1) ëª©í‘œì¹˜: SBP > 90 mmHg, MAP > 65 mmHg   (2) ëª©í‘œì¹˜ë¥¼ ë§ì¶”ê¸° ìœ„í•´ IV crystalloid, vasopressor, inotrope ì‚¬ìš©     4) 12-lead ECG:  STEMI, ë¶ˆì•ˆì •í•œ cardiogenic shock ë“±ì´ ìˆìœ¼ë©´ primary PCI ì‹œí–‰     5)  ëª…ë ¹ì— ë”°ë¥´ëŠ”ì§€ (obeying command) í™•ì¸   (1)  ë”°ë¥´ì§€ ëª»í•˜ë©´ ëª©í‘œì²´ì˜¨ìœ ì§€ì¹˜ë£Œ ì‹œí–‰   (2) ë”°ë¥¸ë‹¤ë©´ ê¸°íƒ€ ì²˜ì¹˜ ì‹œí–‰

</details>

<details>
<summary>2. 1864_4329_ìˆ˜ìˆ  ì „ ì²˜ì¹˜.html (1/5)</summary>

ì œëª©: ìˆ˜ìˆ  ì „ ì²˜ì¹˜  ìˆ˜ìˆ ì€ í™˜ì ê°œì¸ì˜ ì‚¶ì— ìˆì–´ì„œ ë§¤ìš° í° ì‚¬ê±´ì´ë©°, ì‹ ì²´ì ìœ¼ë¡œë„ ë§ì€ ë³€í™”ë¥¼ ë™ë°˜í•˜ë©°, ì´ ì¤‘ ì¶œí˜ˆ ë“± ëª‡ëª‡ì€ ì‹¬ê°í•œ í•©ë³‘ì¦ìœ¼ë¡œ í™˜ìì˜ ì˜ˆí›„ì— í° ì˜í–¥ì„ ë¼ì¹  ìˆ˜ ìˆë‹¤. ë³¸ ë‹¨ì›ì—ì„œëŠ” í™˜ìì˜ ê¸°ì €ì§ˆí™˜ì´ë‚˜ ì•½ë¬¼ë ¥ì— ë”°ë¼ ìˆ˜ìˆ  ì „ ì‹œí–‰í•´ì•¼ í•˜ëŠ” ì¡°ì¹˜ë“¤ì— ëŒ€í•´ ë‹¤ë£¬ë‹¤. íŠ¹íˆ í•­í˜ˆì „ ì•½ë¬¼ì„ ì œì œë³„ë¡œ ì–¸ì œ ëŠì–´ì•¼ í•˜ëŠ”ì§€, ìˆ˜ìˆ  ì „ ì¶œí˜ˆ ë° í˜ˆì „ ê°€ëŠ¥ì„±ì— ëŒ€í•œ ê²€ì‚¬ í•´ì„ê³¼ ì¡°ì¹˜ê°€ ë§ì´ ì¶œì œëœë‹¤.

</details>

<details>
<summary>3. 2440_4450_ì§€ì—­ì‚¬íšŒì •ì‹ ì˜í•™.html (2/2)</summary>

ì œëª©: ì§€ì—­ì‚¬íšŒì •ì‹ ì˜í•™  1. ì…ì›ë°©ë²•   ì •ì‹ ê±´ê°•ì¦ì§„ ë° ì •ì‹ ì§ˆí™˜ì ë³µì§€ì„œë¹„ìŠ¤ ì§€ì›ì— ê´€í•œ ë²•ë¥        ì…ì› ì¢…ë¥˜   ë™ì˜ì˜ ì£¼ì²´   ë¹„ê³          ìì˜ì…ì›   (ì œ41ì¡°)     í™˜ì ë³¸ì¸   í™˜ì ë³¸ì¸ì´ ì›í•˜ì—¬ ì…ì›         ë™ì˜ì…ì›   (ì œ42ì¡°)     ë³´í˜¸ìì˜ë¬´ì   í™˜ìëŠ” ì…ì›ì˜ í•„ìš”ì„±ì„ ëŠë‚Œ         ë³´í˜¸ì˜ë¬´ìì— ì˜í•œ ì…ì›   (ì œ43ì¡°)       ë³´í˜¸ìì˜ë¬´ì 2ëª… ì´ìƒ &   ì •ì‹ ê³¼ ì „ë¬¸ì˜     í™˜ìëŠ” ë¹„ìì˜ì ìœ¼ë¡œ ì…ì›         ìì¹˜ë‹¨ì²´ì¥ì— ì˜í•œ ì…ì›   (ì œ44ì¡°)     ìì¹˜ë‹¨ì²´ì¥ì˜ & ì •ì‹ ê³¼ ì „ë¬¸ì˜           ì‘ê¸‰ì…ì›   (ì œ50ì¡°)     ì˜ì‚¬ & ê²½ì°°ê´€   ì •ì‹ ì§ˆí™˜ì ë¡œ  ìí•´ ë° íƒ€í•´ì˜ ìœ„í—˜ ì´ í´ ë•Œ (ì œ41ì¡°~ì œ44ì¡°ë¥¼ ì ìš©í•  ì‹œê°„ì  ì—¬ìœ ê°€ ì—†ìŒ)             Kaplan & Sadock 12e, Ch.30

</details>

<details>
<summary>4. 1711_4015_ì„±í­í–‰.html (2/5)</summary>

ì œëª©: ì„±í­í–‰  1. ê°œìš”   1) ì§„ì°° ì „ë°˜ì— ëŒ€í•œ ì£¼ì˜ì‚¬í•­   (1) ê°ê´€ì , ë¬´ë¹„íŒì  íƒœë„   (2) ìµœì†Œ 1ì¸ì˜ ì…íšŒì¸ ë™ë°˜ (ì˜ë£Œì§„ ë‘˜ ì¤‘ í•œ ëª…ì€ í”¼í•´ìì™€ ê°™ì€ ì„±ë³„)   (3) ê³¼ì • ì „ì²´ë¥¼ í”¼í•´ìì—ê²Œ ì„¤ëª…í•˜ë©° ì§„í–‰     2) ì„±í­ë ¥ ì‘ê¸‰í‚¤íŠ¸: ì—¬ì„±ê°€ì¡±ë¶€ì—ì„œ ì œì‘í•˜ì—¬ ë³‘ì›ì— ë°°í¬í•˜ëŠ” ì •í˜•í™”ëœ ì¦ê±°ìˆ˜ì§‘ í‚¤íŠ¸   (1)  ë™ì˜ì„œ :   ê°€ì¥ ë¨¼ì € í™•ë³´ í›„ ì§„ì°° ì‹œì‘   (2) ì§„ë£Œê¸°ë¡ ì‘ì„±   (3) ì˜ë¥˜ ìˆ˜ê±°   (4) ë¶€ìŠ¤ëŸ¬ê¸°, ê°€í•´ì ì²´ì•¡/ìŒëª¨ ì±„ì·¨:  ìš°ë“œë“± (Wood's lamp)ìœ¼ë¡œ ê°€í•´ì  ì •ì•¡  í™•ì¸ ê°€ëŠ¥ (ì²­ë¡ìƒ‰ or ì£¼í™©ìƒ‰ í˜•ê´‘)     (5) ì§ˆ/ìê¶ê²½ë¶€, í•­ë¬¸/ì§ì¥, êµ¬ê°• ë©´ë´‰ ë„ë§: ì •ì ìœ ë¬´ í™•ì¸, ì„±ë§¤ê°œê°ì—¼ì— ëŒ€í•œ ì§„ë‹¨ê²€ì‚¬(PCR, ë°°ì–‘ ë“±)   (6) í”¼í•´ì í˜ˆì•¡/ì†Œë³€     3) ì˜í•™ì  ê¸°ë³¸ ê²€ì‚¬   (1) ì„ì‹  ê²€ì‚¬:  ì†Œë³€ ì„ì‹ ë°˜ì‘ê²€ì‚¬, í˜ˆì¤‘ Î²-hCG ë“±   (2) ì„±ë§¤ê°œê°ì—¼ PCR or ë°°ì–‘   â‘  ì„ì§ˆê·  (Neisseria gonorr

</details>

<details>
<summary>5. 1789_4131_ê¸‰ì„± ê°„ë¶€ì „.html (4/4)</summary>

ì œëª©: ê¸‰ì„± ê°„ë¶€ì „  3. ì¹˜ë£Œ   1) ë³´ì¡´ì  ì¹˜ë£Œ:  ì¤‘í™˜ìì‹¤ ì…ì‹¤ ë° ì² ì €í•œ monitoring   (1) í˜ˆì—­í•™ì  ì•ˆì •: ìˆ˜ì•¡ì¹˜ë£Œ â†’ í•„ìš”ì‹œ norepinephrine ë“± vasopressor   (2) ì „í•´ì§ˆ êµì •   (3) ì˜ì–‘: ì €í˜ˆë‹¹ ì˜ˆë°©, ì¥ê´€ì˜ì–‘ ë“±     2) ì›ì¸ì— ëŒ€í•œ ì¹˜ë£Œ   (1) ë°”ì´ëŸ¬ìŠ¤: HBVì˜ ê²½ìš° tenofovir ë“±, HSVì˜ ê²½ìš° acyclovir ë“±   (2) ë…ì„±/ì•½ì¸ì„±: N-acetylcysteine ê³ ë ¤, ë…ë²„ì„¯ì˜ ê²½ìš° silibinin ë“±   (3) ìê°€ë©´ì—­: Steroid     3) í•©ë³‘ì¦ë“¤ì— ëŒ€í•œ ì¹˜ë£Œ   (1) ê°„ì„± í˜¼ìˆ˜: Lactulose â†’ ì§€ì†ì„±ì‹ ëŒ€ì²´ìš”ë²•(CRRT) ê³ ë ¤   (2) ë‡Œë¶€ì¢…: Mannitol, 3% NaCl   (3) ì‘ê³ ì¥ì• : ì¶œí˜ˆ or ê³ ìœ„í—˜ ìˆ ê¸° ì‹œ FFP, PLT ìˆ˜í˜ˆ ë“±   (4) ê°ì—¼: ê´‘ë²”ìœ„ í•­ìƒì œ     4)  ê°„ì´ì‹ (liver transplantation, LT)   (1) ë¹„ê°€ì—­ì  ê°„ë¶€ì „ì‹œ

</details>

<details>
<summary>6. 1868_4327_ë±€ë¬¼ë¦¼ê³¼ ë™ë¬¼ë¬¼ë¦¼.html (5/7)</summary>

ì œëª©: ë±€ë¬¼ë¦¼ê³¼ ë™ë¬¼ë¬¼ë¦¼  4. ë³‘ì› ì´ì†¡ í›„ ì²˜ì¹˜   1) ë³‘ë ¥ì²­ì·¨: ìƒì²˜ ì…ì€ ì‹œê°„, ë±€ì˜ ì¢…ë¥˜, ê³¼ê±°ë ¥     2) ì¶”ê°€ì  ìƒíƒœ íŒŒì•…: CXR, ECG, ë±€ ì¢…ë¥˜ì— ë”°ë¼ 6~8ë¶€í„° 24ì‹œê°„ê¹Œì§€ ê´€ì°°   (1) ì‘ê³ ì¥ì• : CBC, PT/INR/aPTT, fibrinogen, FDP   (2) ì‹ ë¶€ì „: CK, BUN/Cr, urinalysis(hematuria, proteinuria)   (3) ìˆ˜í˜ˆ ëŒ€ë¹„: blood type and cross-matching     3) ì¹˜ë£Œ   (1) ì¤‘ë“±ë„ ì´ìƒì˜ ì‹¬ê°ë„ â†’  ì¡°ê¸° í•­ë…ì†Œ ì¹˜ë£Œ  (anaphylaxis ëŒ€ì²˜ê°€ ê°€ëŠ¥í•  ë•Œë§Œ ì‹œí–‰)   (2) ì ì ˆí•œ í•­ë…ì†Œ ì¹˜ë£Œì—ë„  êµ¬íšì¦í›„êµ° Â ë°œìƒ Â â†’  ê·¼ë§‰ì ˆê°œìˆ 

</details>

<details>
<summary>7. 1636_4736_íŒ¨í˜ˆì¦.html (2/5)</summary>

ì œëª©: íŒ¨í˜ˆì¦  1. ê°ì—¼ì§ˆí™˜ì˜ ì ‘ê·¼   1) ë°œì—´   (1) ê³ ë ¹, ë©´ì—­ì €í•˜ìëŠ” ë°œì—´ì´ ë‚˜íƒ€ë‚˜ì§€ ì•Šê¸°ë„ í•¨   (2)  ì €ì²´ì˜¨ : ê°ì—¼ì´ ì‹¬í•  ê²½ìš° ë°œìƒ ê°€ëŠ¥   (3) ì¦ìƒì˜ ê¸°ë³¸ ì •ë³´: Onset, duration, ì•…í™”ì˜ ì—¬ë¶€ ë° ìœ ë°œìš”ì¸ ë“±     2) ê²€ì²´ ì±„ì·¨ ë° ê²½í—˜ì  í•­ìƒì œ   (1)  ë°°ì–‘ì„ ìœ„í•œ ê²€ì²´ ì±„ì·¨ í›„ í•­ìƒì œ íˆ¬ì—¬ê°€ ì›ì¹™   â‘  í˜ˆì•¡ë°°ì–‘: ì¼ë°˜ì ìœ¼ë¡œ 2ìŒ, ì‹¬ë‚´ë§‰ì—¼ì˜ ê²½ìš° 3ìŒ   â‘¡ ê°ë‹´ë°°ì–‘: íë ´ ë“± í˜¸í¡ê¸° ì§ˆí™˜ì˜ ê²½ìš°   â‘¢ ì†Œë³€ë°°ì–‘: ì‹ ìš°ì‹ ì—¼ ë“± ì‹ ì¥ë¹„ë‡¨ê¸° ì§ˆí™˜ì˜ ê²½ìš°   â‘£ ì¹´í…Œí„° íŒ ë°°ì–‘: ì¤‘ì‹¬ì •ë§¥ê´€ ë“±  ë„ê´€ ê°ì—¼ ì´ ì˜ì‹¬ë  ê²½ìš°   (2) ë‡Œìˆ˜ë§‰ì—¼ ì˜ì‹¬ ì‹œ ì²™ìˆ˜ì²œì â†’ CSF ê²€ì²´ ì±„ì·¨ â†’ í•­ìƒì œ íˆ¬ì—¬   â‘  í•­ìƒì œ íˆ¬ì—¬ ì „ì— ì‹¤ì‹œ   â‘¡ ë‹¨, ì•„ë˜ì˜ ê²½ìš° í˜ˆì•¡ê²€ì²´ ì±„ì·¨ë§Œ ì™„ë£Œí•˜ê³  ë°”ë¡œ í•­ìƒì œ íˆ¬ì—¬   â€¢  IICPê°€ ì˜ì‹¬ë˜ì–´ ì²™ìˆ˜ì²œì ì „ ì˜ìƒê²€ì‚¬ë¥¼ ë¨¼ì € ì§„í–‰í•´ì•¼ í•  ë•Œ   â€¢  ì²™ìˆ˜ì²œìì˜ ì²« ì‹œë„ê°€ ì‹¤íŒ¨í–ˆì„ ë•Œ   * ì›ë˜ ê²€ì²´ ì±„ì·¨ í›„ í•­

</details>

<details>
<summary>8. 1864_4329_ìˆ˜ìˆ  ì „ ì²˜ì¹˜.html (5/5)</summary>

ì œëª©: ìˆ˜ìˆ  ì „ ì²˜ì¹˜  4. ìˆ˜ìˆ  ì „ ê¸ˆì‹       ë¶„ë¥˜   ê¸ˆì‹ ê¸°ê°„       Clear liquid: ë¬¼, ì£¼ìŠ¤ ë“±   ìˆ˜ìˆ  ì‹œì‘ 2ì‹œê°„ ì „       ëª¨ìœ    ìˆ˜ìˆ  ì‹œì‘ 4ì‹œê°„ ì „       ê³ í˜•ì‹: Light meal   ìˆ˜ìˆ  ì‹œì‘ 6ì‹œê°„ ì „       ê³ í˜•ì‹: Heavy meal   ìˆ˜ìˆ  ì‹œì‘ 8ì‹œê°„ ì „       * Aspirationì„ ì˜ˆë°©í•˜ê¸° ìœ„í•œ ëª©ì ì˜ ì¼ê´„ì ì¸ GI stimulant, antacid, antiemetic, anticholinergic íˆ¬ì—¬ëŠ” ê¶Œê³ ë˜ì§€ ì•ŠëŠ”ë‹¤.       Sabiston 21e, pp.192-208   UpToDate. Perioperative medication management

</details>

<details>
<summary>9. 1804_4172_ê°ì—¼ ì‹¬ë‚´ë§‰ì—¼.html (6/6)</summary>

ì œëª©: ê°ì—¼ ì‹¬ë‚´ë§‰ì—¼  5. ì¹˜ê³¼ ì¹˜ë£Œ ì‹œ ì˜ˆë°©   1) ê°œë…: ì¹˜ê³¼ ì¹˜ë£Œ ì‹œ êµ¬ê°• ì ë§‰ ì†ìƒ â†’  íŠ¹ì • í™˜ìêµ°ì˜ ê²½ìš° IE ë°œìƒ ìœ„í—˜ì´ ë†’ì•„ ì˜ˆë°©ì  í•­ìƒì œ í•„ìš”   (1) ë°œì¹˜   (2) ì‡ëª¸/ì¹˜ì•„ë¿Œë¦¬ë¥¼ ê±´ë“œë¦¬ëŠ” ì‹œìˆ    (3) ê¸°íƒ€ ìˆ˜ìˆ : ì„í”Œë€íŠ¸, ì¹˜ì£¼ìˆ˜ìˆ , êµ¬ê°• ë‚´ ìƒê²€ ë“±     2) ì˜ˆë°©ì  í•­ìƒì œ:  ì¹˜ê³¼ ì¹˜ë£Œ ì‹œì‘  30~60ë¶„ ì „   â€¢  Amoxicillin  2g PO, ampicillin 2g IM/IV, cefazolin 1g IM/IV, ceftriaxone 1g IM/IV     3) ì ì‘ì¦   (1) ì´ì „ IE ë³‘ë ¥   (2)   ì¸ê³µ íŒë§‰ ,  íŒë§‰ ê´€ë ¨ ê¸°íƒ€ ì¸ê³µ ì‚½ì…ë¬¼, ì‹¬ì‹¤ë³´ì¡°ì¥ì¹˜   (3) ì„ ì²œì„± ì‹¬ì§ˆí™˜: ì•„ë˜ì™€ ê°™ì„ ê²½ìš°ì—ë§Œ ì‹œí–‰   â‘  êµì •ë˜ì§€ ì•Šì€ ì„ ì²œì„± ì²­ìƒ‰ì¦ ì‹¬ì§ˆí™˜   â‘¡   íŒë§‰ì„± ì¸ê³µì‚½ì…ë¬¼ or ì¸ê³µì ì¸ systemic-pulmonary shuntë¥¼ ì´ìš©í•´ êµì •í•œ ì„ ì²œì„± ì‹¬ì§ˆí™˜   â‘¢ ì„ ì²œì„± ì‹¬ì§ˆí™˜ êµì • í›„ 6ê°œì›” ì´ë‚´ or resid

</details>

<details>
<summary>10. 1864_4329_ìˆ˜ìˆ  ì „ ì²˜ì¹˜.html (3/5)</summary>

ì œëª©: ìˆ˜ìˆ  ì „ ì²˜ì¹˜  2. ìˆ˜ìˆ  ì „ ìˆ˜í˜ˆ   * ìì„¸í•œ ë‚´ìš©ì€ â€˜ í˜ˆì•¡ì œì œ íˆ¬ì—¬ ì§€ì¹¨ â€™ ë‹¨ì› ì°¸ê³      pRBC     â€¢  Hb < 7g/dL   â€¢ Hb < 8g/dL + ì‹¬í˜ˆê´€ê³„ ì§ˆí™˜   â€¢ ì¤‘ì¦ ì™¸ìƒí™˜ì     PLT     â€¢ ì¶œí˜ˆ ì—†ëŠ” ì•ˆì •ìƒíƒœ: 10,000~20,000/mm 3   â€¢ ì¶œí˜ˆ ì—†ëŠ” ë¶ˆì•ˆì •ìƒíƒœ: 20,000~50,000/mm 3   â€¢ ì¼ë°˜ì ì¸ ì¶œí˜ˆ or ì‹œìˆ  or ìˆ˜ìˆ : 50,000~100,000/mm 3   â€¢ ì¥ê¸°ì˜ ì‹¬ê°í•œ í•©ë³‘ì¦ì„ ìœ ë°œí•  ìˆ˜ ìˆëŠ” ì¶œí˜ˆ or ìˆ˜ìˆ : < 100,000/mm 3     FFP     â€¢ ì‘ê³ ì¸ì ê²°í•ìœ¼ë¡œ ì¸í•œ ì¶œí˜ˆ   â€¢ PT > ì •ìƒ ì¤‘ê°„ê°’ Ã— 1.5ë°° (or INR â‰¥ 1.7)   â€¢ aPTT > ì •ìƒ ìƒí•œê°’ Ã— 1.5ë°°   â€¢ ì‘ê³ ì¸ì ê²°í•: íŠ¹íˆ V, XI   â€¢ ì„¬ìœ ì†Œì›(fibrinogen) < 100 mg/dL   â€¢ í˜ˆì¥êµí™˜ìˆ (plasmapheresis)

</details>

### ğŸ’¬ Answer
The provided context does not directly address the initial management of a patient presenting with acute heart failure. However, based on general medical knowledge and principles derived from the provided texts, I can infer appropriate initial steps.  Specifically, the text regarding "ROSC í™˜ìì˜ ì²˜ì¹˜" (treatment of patients with Return of Spontaneous Circulation) after cardiac arrest, though not directly about heart failure, provides a framework for initial stabilization that is applicable.  Additionally, the section on "ê¸‰ì„± ê°„ë¶€ì „" (acute liver failure) addresses general principles of critical care management that are relevant.

Here's a breakdown of the initial management approach, incorporating relevant elements from the provided texts and general medical knowledge:

**I. Initial Assessment and Stabilization (adapted from ì‹¬ì •ì§€ í›„ í•©ë³‘ì¦ - ROSC í™˜ìì˜ ì²˜ì¹˜, and ê¸‰ì„± ê°„ë¶€ì „):**

1.  **Airway, Breathing, Circulation (ABCs):** This is the foundational principle.
    *   **Airway:** Assess airway patency.  If the patient is unable to protect their airway or is in severe respiratory distress, intubation may be necessary.
    *   **Breathing:**
        *   **Oxygenation:** Immediately administer high-flow oxygen (100%) initially.  The goal is to achieve adequate oxygen saturation (SpO2).  The target SpO2 is generally 92-98% (as mentioned in the ROSC protocol).
        *   **Ventilation:** Assess respiratory rate and depth. Assisted ventilation (e.g., bag-valve-mask ventilation or mechanical ventilation after intubation) may be required if the patient is not breathing adequately or if there is severe respiratory distress.  Consider a respiratory rate of 10 breaths/min, as noted in the ROSC protocol.
        *   **Arterial Blood Gas (ABG):** Obtain an ABG to assess oxygenation (PaO2), ventilation (PaCO2), and acid-base balance.  The target PaCO2 is generally 35-45 mmHg (as noted in the ROSC protocol).
    *   **Circulation:**
        *   **Cardiac Monitoring:**  Attach the patient to a cardiac monitor to assess heart rate and rhythm.
        *   **Blood Pressure:**  Assess blood pressure. Hypotension is common in acute heart failure.
        *   **IV Access:** Establish intravenous (IV) access for medication administration and fluid resuscitation (if needed).
        *   **Fluid Management:**  Carefully assess the patient's volume status.  While hypotension may be present, aggressive fluid administration can worsen heart failure.  If the patient is hypotensive, a small fluid bolus (e.g., 250-500 mL of crystalloid) may be given while closely monitoring for signs of fluid overload (e.g., pulmonary edema).
        *   **Vasopressors/Inotropes:** If hypotension persists despite initial fluid resuscitation, consider vasopressors (e.g., norepinephrine) or inotropes to improve cardiac output and blood pressure.  The target SBP is > 90 mmHg and MAP > 65 mmHg (as noted in the ROSC protocol).

2.  **12-Lead ECG:** Obtain a 12-lead ECG to assess for evidence of myocardial ischemia or infarction (STEMI) or other arrhythmias contributing to the heart failure.  If STEMI is present, emergent PCI is indicated (as noted in the ROSC protocol).

3.  **History and Physical Examination:** Obtain a focused history and physical examination to determine the underlying cause of the heart failure and assess the severity of symptoms.  Key elements include:
    *   History of present illness (onset, duration, severity of symptoms)
    *   Past medical history (including history of heart disease, hypertension, diabetes, kidney disease)
    *   Medications (including diuretics, ACE inhibitors, beta-blockers)
    *   Allergies
    *   Physical examination: Assess for signs of heart failure (e.g., jugular venous distension, pulmonary edema, peripheral edema, S3 gallop).

4.  **Laboratory Studies:** Obtain relevant laboratory studies to assess the severity of heart failure and identify potential underlying causes or contributing factors.  These may include:
    *   Complete blood count (CBC)
    *   Electrolytes (including sodium, potassium, chloride, bicarbonate)
    *   Blood urea nitrogen (BUN) and creatinine (to assess renal function)
    *   Cardiac biomarkers (troponin) to assess for myocardial injury
    *   Brain natriuretic peptide (BNP) or N-terminal pro-BNP (NT-proBNP) to assess the severity of heart failure
    *   Liver function tests (LFTs)
    *   Coagulation studies (PT/INR, aPTT)

**II. Initial Treatment:**

1.  **Oxygen Therapy:** As mentioned above, maintain adequate oxygenation.

2.  **Diuretics:** Administer diuretics (e.g., furosemide) to reduce fluid overload.

3.  **Vasodilators:** Consider vasodilators (e.g., nitroglycerin) to reduce preload and afterload.

4.  **Morphine:** May be considered for symptom relief (dyspnea, anxiety) but use cautiously due to potential respiratory depression and hypotension.

5.  **Positioning:** Place the patient in an upright position to improve breathing.

**In summary, the first steps in managing a patient with acute heart failure are focused on stabilizing the patient's airway, breathing, and circulation, obtaining a 12-lead ECG, and initiating appropriate medical therapy to reduce fluid overload and improve cardiac function.  A thorough history and physical examination, along with relevant laboratory studies, are essential to determine the underlying cause of the heart failure and guide further management.**

---
